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INTRODUCTION: 
Diabetes is the leading cause of neuropathy in the Western world, and neuropathy is the most 
common complication and greatest source of morbidity and mortality in diabetes patients.[1] 
Peripheral neuropathy is the most common chronic complication of DM and can involve any 
peripheral nerve. It is a major cause of morbidity among patients with DM [2]. The prevalence 
and pattern of PN vary from country to country, from as low as 1.5% to as high as 100%  in 
patients with type 2 diabetes [3-8] depending on the differences in screening approaches, 
diagnostic criteria and the study population. The neuropathy may be silent and go undetected. 
Up to 7.5% of patients with type 2 diabetes have clinical neuropathy at the time of diagnosis. 
This rate increases to 50% among patients with diabetes who have had diabetes for 25 
years.8.However, epidemiological studies of the impact of PN on type 2 diabetes in 
developing countries are scarce. 
 DN is a set of clinical syndromes that affect distinct regions of the nervous system, singly or 
combined. It may be silent and go undetected, while exercising its ravages or it may present 
with clinical symptoms and signs that although nonspecific and insidious with slow 
progression but also mimic those seen in many other diseases. It is, therefore, diagnosed by 
exclusion. Neurologic complications occur equally in type 1 and type 2 diabetes mellitus and 
additionally in various forms of acquired diabetes. . Progression of DN is related to glycemic 
control in both type 1 and type 2 diabetes. Sensory and autonomic neuropathies generally 
progress, while mononeuropathies, radiculopathies, and acute painful neuropathies, although 
symptoms are severe, are short-lived and tend to recover. 
With improvement in treatment, the prevalence of type1 and type2 DM is likely to increase, 
as more individuals will live longer. Recent reports have concluded that if the aetiology is 
hyperglycemia, it’s reversible on treatment. The study of risk factors for development of 
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diabetic peripheral neuropathy has revealed that increased age, longer duration of diabetes 
and poor glycemic control were significant risk factors 9.The  National diabetes information 
clearing house ,has estimated that 50% of the diabetics have some form of neuropathy among 
the people who have had the disease for at least 25years10With linear increase in prevalence 
of neuropathy, it is therefore pertinent to look at the risk determinants of diabetic neuropathy 
as this will improve diabetes care. The present study aims at identifying the risk factors of 
diabetic neuropathy. 
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 AIMS AND OBJECTIVES: 
 
The objective of the study is to identify the risk factors associated with distal symmetrical 
peripheral neuropathy in type 2 diabetes mellitus patients who are attending diabetology out 
patient department in Thanjavur Medical College Hospital.   
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REVIEW OF LITERATURE: 
The worldwide prevalence of DM has risen dramatically over the past two decades, from an 
estimated 30 million cases in 1985 to 177 million in 2000. Based on current trends, >360 
million individuals will have diabetes by the year 2030. Although the prevalence of both type 
1 and type 2 DM is increasing worldwide, the prevalence of type 2 DM is rising much more 
rapidly because of increasing obesity and reduced activity levels as countries become more 
industrialized. This is true in most countries, and 6 of the top 10 countries with the highest 
rates are in Asia. DM increases with aging. The prevalence is similar in men and women 
throughout most age ranges but is slightly greater in men >60 years.  
Diabetes is a major cause of mortality, but several studies indicate that diabetes is likely 
underreported as a cause of death. A recent estimate suggested that diabetes was the fifth 
leading cause of death worldwide and was responsible for almost 3 million deaths annually  
The National Diabetes Data Group and World Health Organization have issued diagnostic 
criteria for DM based on the following premises: 
 (1) The spectrum of fasting plasma glucose (FPG) and the response to an oral glucose load 
(OGTT—oral glucose tolerance test) varies among normal individuals, and  
(2) DM is defined as the level of glycemia at which diabetes-specific complications occur 
rather than on deviations from a population-based mean 
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Criteria for the Diagnosis of Diabetes Mellitus 
 
 
 Symptoms of diabetes plus random blood glucose concentration 11.1 mmol/L 
(200 mg/dL) or  
 Fasting plasma glucose 7.0 mmol/L (126 mg/dL) or  
 Two-hour plasma glucose 11.1 mmol/L (200 mg/dL) during an oral glucose 
tolerance test 
 
 
 
The chronic complications of DM affect many organ systems and are responsible for the 
majority of morbidity and mortality associated with the  disease. Chronic complications can 
be divided into vascular and nonvascular complications  
VASCULAR 
MICROVASCULAR 
Eye disease 
  Retinopathy 
   Macular edema 
Neuropathy 
  Sensory and motor ( nonproliferative/proliferative ) 
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  Autonomic 
Nephropathy 
MACROVASCULAR 
 Coronary artery disease 
 Peripheral arterial disease 
 Cerebrovascular disease 
Other 
Gastrointestinal (gastroparesis, diarrhea) 
 
Genitourinary (uropathy/sexual dysfunction) 
 
Dermatologic 
 
Infectious 
 
Cataracts 
 
Glaucoma 
 
Periodontal disease 
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The risk of chronic complications increases as a function of the duration of hyperglycemia; 
they usually become apparent in the second decade of hyperglycemia. Since type 2 DM often 
has a long asymptomatic period of hyperglycemia, many individuals with type 2 DM have 
complications at the time of diagnosis. 
The microvascular complications of both type 1 and type 2 DM result from chronic 
hyperglycemia. Large, randomized clinical trials of individuals with type 1 or type 2 DM 
have conclusively demonstrated that a reduction in chronic hyperglycemia prevents or delays 
retinopathy, neuropathy, and nephropathy. Other incompletely defined factors may modulate 
the development of complications. Many of these patients have glycemic control that is 
indistinguishable from those who develop microvascular complications, suggesting that there 
is a genetic susceptibility for developing particular complications. 
Evidence implicating a causative role for chronic hyperglycemia in the development of 
macrovascular complications is less conclusive. However, coronary heart disease events and 
mortality are two to four times greater in patients with type 2 DM. These events correlate 
with fasting and postprandial plasma glucose levels as well as with the A1C. Other factors 
(dyslipidemia and hypertension) also play important roles in macrovascular complications. 
DIABETIC NEUROPATHIES  
Diabetic neuropathies are a heterogeneous group of disorders and present a wide range of 
abnormalities. They are among the most common long-term complications of diabetes and 
are a significant source of morbidity and mortality.[12,13] Estimates of the prevalence of 
neuropathy vary substantially, depending on specific diagnostic criteria.[14,15] In the United 
States, prevalence estimates have ranged from 5% to 100%.[12,14,15–17] 
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 In Pirart's classic study of a cohort of 4400 patients, prevalence was found to reach 
approximately 45% after 25 years.[18] Furthermore, it is now evident that neuropathy can 
occur with impaired glucose tolerance[19] and with the metabolic syndrome in the absence 
of hyperglycemia.[20] It is the most common form of neuropathy in the developed countries 
of the world, accounts for more hospitalizations than all the other diabetic complications 
combined, and is responsible for 50% to 75% of nontrauma amputations.[16,17]  
Diabetic peripheral neuropathy is also responsible for weakness and ataxia, with an 
estimated increase in likelihood of falling that is 15 times that of unaffected 
population.[21,22] 
The true prevalence is not known and depends on the criteria and methods used to define 
neuropathy. Of patients attending a diabetes clinic, 25% volunteered symptoms, but 50% 
were found to have neuropathy after a simple clinical test such as the ankle jerk or 
vibration perception test. Almost 90% tested positive to sophisticated tests of autonomic 
function or peripheral sensation.[23] Neurologic complications occur equally in T1DM and 
T2DM and additionally in various forms of acquired diabetes.[15]Neuropathy increases the 
risk of amputation 1.7-fold, 12-fold if there is deformity (itself a consequence of 
neuropathy), and 36-fold if there is a history of previous ulceration.[24]  
There are 86,000 amputations in the United States each year, one every 10 minutes, and 
neuropathy is the major contributor in 87% of cases.[13] Once autonomic neuropathy sets 
in, life can become quite dismal, and the mortality rate approximates 25% to 50% within 5 
to 10 years.[25–28] 
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Classification  
Diabetic neuropathy is not a single entity but a number of different syndromes with 
subclinical or clinical manifestations depending on the classes of nerve fibers involved. 
According to the San Antonio Convention,[29] the main groups of neurologic disturbance in 
diabetes mellitus include:  
   
•    Subclinical neuropathy, which is determined by abnormalities in electrodiagnostic 
and quantitative sensory testing 
   
•    Diffuse clinical neuropathy with distal symmetric sensorimotor and autonomic 
syndromes 
   •    Focal syndromes 
Subclinical neuropathy is diagnosed on the basis of abnormal electrodiagnostic tests with 
decreased nerve conduction velocity (NCV) or decreased amplitudes; abnormal 
quantitative sensory tests (QST) for vibration, tactile, thermal warming, and cooling 
thresholds; and quantitative autonomic function tests (QAFT) revealing diminished heart 
rate variation with deep breathing, Valsalva maneuver, and postural testing.  
 
Natural History  
The natural history of neuropathies separates them into two very distinct entities, namely 
those that progress gradually with increasing duration of diabetes and those that remit, 
usually completely. Sensory and autonomic neuropathies generally progress, and 
mononeuropathies, radiculopathies, and acute painful neuropathies, although symptoms are 
severe, are short-lived, and patients tend to recover.[30] 
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Progression of neuropathy is related to glycemic control in both T1DM and T2DM.[31,32] In 
T2DM, slowing of NCVs may be one of the earliest neuropathic abnormalities and often is 
present even at diagnosis.[33] After diagnosis, slowing of NCV generally progresses at a 
steady rate of approximately 1 m/sec per year, and the level of impairment is positively 
correlated with duration of diabetes. In a long-term follow-up study of T2DM patients,[34] 
electrophysiologic abnormalities in the lower limb increased from 8% at baseline to 42% 
after 10 years. 
It has always been assumed that diabetes affects the longest fibers first—hence, the 
increased predisposition in taller persons.[35] 
Now it seems that small-fiber involvement can herald the onset of neuropathy and even 
diabetes. Small-fiber function is not detectable using standard electrophysiology and 
requires measurement of sensory, neurovascular, and autonomic thresholds and cutaneous 
nerve fiber density.[20,36–38] There are few data on the longitudinal trends in small-fiber 
dysfunction, although it appears that the nerve fiber loss in prediabetic neuropathy might 
respond to lifestyle changes.[39] 
Much remains to be learned of the natural history of diabetic autonomic neuropathy. 
Karamitsos and colleagues[40] have reported that the progression of diabetic autonomic 
neuropathy is significant during the 2 years subsequent to its discovery. The mortality rate 
for diabetic autonomic neuropathy has been estimated to be 44% within 2.5 years of 
diagnosing symptomatic autonomic neuropathy.[25]A meta-analysis[41] revealed that the 
mortality rate after 5.8 years of diabetes with symptomatic autonomic neuropathy was 
29%. In a meta-analysis of 12 published studies, reduced cardiovascular function as 
measured by heart rate variability was shown to be associated with an increased risk of 
silent myocardial infarction.[28]The relative risk of mortality from 15 studies (N=2900; 
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95% CI) was increased in patients with cardiac autonomic neuropathy by 2.14 (CI 1.83-
2.51).[28]  
Pathophysiology 
The factors leading to the development of peripheral neuropathy in diabetes are not 
understood completely, and multiple hypotheses have been advanced. It is generally accepted 
to be a multifactorial process. Important contributing biochemical mechanisms in the 
development of the more common symmetrical forms of diabetic polyneuropathy likely 
include the following:  
 
 
 Management aimed at pathogenic mechanisms. AII, angiotensin II; A-V, arteriovenous; 
EDHF, endothelium-derived hyperpolarizing factor; EFA, essential fatty acid; ET, 
endothelin; NO, nitric oxide; PGI2, prostaglandin I2.   
(Adapted from Vinik A, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 
2004;88(4):947-999.)  
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Polyol pathway 
Hyperglycemia causes increased levels of intracellular glucose in nerves, leading to 
saturation of the normal glycolytic pathway. Extra glucose is shunted into the polyol pathway 
and converted to sorbitol and fructose by the enzymes aldose reductase and sorbitol 
dehydrogenase. Accumulation of sorbitol and fructose lead to reduced nerve myoinositol, 
decreased membrane Na+/K+ -ATPase activity, impaired axonal transport, and structural 
breakdown of nerves, causing abnormal action potential propagation. This is the rationale for 
the use of aldose reductase inhibitors to improve nerve conduction.42 
Advanced glycation end products (AGE) 
 
The nonenzymatic reaction of excess glucose with proteins, nucleotides, and lipids results in 
advance glycation end products that may have a role in disrupting neuronal integrity and 
repair mechanisms through interference with nerve cell metabolism and axonal transport.43   
Oxidative stress 
The increased production of free radicals in diabetes may be detrimental via several 
mechanisms that are not fully understood. These include direct damage to blood vessels 
leading to nerve ischemia and facilitation of AGE reactions. Despite the incomplete 
understanding of these processes, use of the antioxidant alpha lipoic acid may hold promise 
for improving neuropathic symptoms.44 
Clinical Presentation  
An international consensus meeting on the outpatient diagnosis and management of 
diabetic neuropathy agreed that a simple definition of diabetic neuropathy was “the 
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presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes 
after the exclusion of other causes.”[29]  
The importance of excluding nondiabetic causes was emphasized in the Rochester Diabetic 
Neuropathy Study, in which up to 10% of peripheral neuropathy in diabetic patients was 
deemed to be of nondiabetic etiology.[15]  
A more detailed definition of neuropathy had previously been agreed on at the San Antonio 
Consensus Conference: “Diabetic neuropathy is a descriptive term meaning a demonstrable 
disorder, either clinically evident or sub-clinical, that occurs in the setting of diabetes 
mellitus without other causes for peripheral neuropathy. The neuropathic disorder includes 
manifestations in the somatic and/or autonomic parts of the peripheral nervous system.”[29] 
In the goal A1c study,[45] identification of the absence of neuropathy in 7000 patients was 
fairly adequate but was only accurate in the presence of mild neuropathy one third of the 
time, and it reached 75% only if neuropathy was severe. Clearly there is a need for 
education of the means whereby neuropathy may be diagnosed. 
Focal Neuropathies  
Mononeuropathies occur primarily in the older population. Their onset is generally acute 
and associated with pain, and their course is self-limiting, resolving within 6 to 8 weeks. 
Mononeuropathies result from vascular obstruction after which adjacent neuronal fascicles 
take over the function of those infarcted by the clot.[46] Common entrapment sites in 
diabetic patients involve median, ulnar, and radial nerves; femoral nerves, lateral cutaneous 
nerves of the thigh, and peroneal nerves; and the medial and lateral plantar nerves.  
Carpal tunnel syndrome occurs three times as often in persons with diabetes compared with a 
normal, healthy population,[47,48] and its increased prevalence in diabetes may be related to 
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diabetic cheiroarthropathy,[49] repeated undetected trauma, metabolic changes, or 
accumulation of fluid or edema within the confined space of the carpal tunnel.[50]  
 
DIFFUSE NEUROPATHIES  
Proximal Motor Neuropathies  
The condition has a number of synonyms; proximal neuropathy, femoral neuropathy, 
diabetic amyotrophy, and diabetic neuropathic cachexia. 
The condition is now recognized as secondary to a variety of causes that are unrelated to 
diabetes but that have a greater incidence in patients with diabetes than in the general 
population. This includes patients with chronic inflammatory demyelinating 
polyneuropathy (CIDP), monoclonal gammopathy, circulating GM1 antibodies and 
antibodies to neuronal cells, and inflammatory vasculitis.[51,52] However, immune-mediated 
neuropathy can resolve within days on immunotherapy. 
In the classic form of diabetic amyotrophy, axonal loss is the predominant process, and the 
condition coexists with DSPN.[53] Electrophysiologic evaluation reveals lumbosacral 
plexopathy.[54] 
If demyelination predominates and the motor deficit affects proximal and distal muscle 
groups, the diagnosis of CIDP, monoclonal gammopathy of unknown significance 
(MGUS), and vasculitis should be considered.[55,56] It seems probable that these conditions 
occur more commonly in people with diabetes.[57,58] Sharma examined more than 1000 
patients with neurologic disorders and found that CIDP was 11 times more common 
among their diabetic than the nondiabetic population.[58] 
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Distal Symmetric Polyneuropathy  
Distal symmetric polyneuropathy (DSPN) is the most common and widely recognized 
form of diabetic neuropathy. The onset is usually insidious but occasionally is acute, 
following stress or initiation of therapy for diabetes. DSPN may be either sensory or motor 
and can involve small fibers, large fibers, or both.[59]  
Small nerve fiber dysfunction usually occurs early and often is present without objective 
signs or electrophysiologic evidence of nerve damage.[60] It is manifested early with 
symptoms of pain and hyperalgesia in the lower limbs, followed by a loss of thermal 
sensitivity and reduced light touch and pinprick sensation.[50] 
There is now evidence that DSPN may be accompanied by loss of cutaneous nerve fibers 
that stain positive for the neuronal antigen panaxonal marker protein gene product 9.5 
(PGP 9.5)[61] and by impaired neurovascular blood flow.[62] The importance of the skin 
biopsy as a diagnostic tool for diabetic peripheral neuropathy is increasingly being 
recognized.[20,36,63,64] This technique quantitates small epidermal nerve fibers through 
antibody staining of PGP 9.5.[65,66,67] Though minimally invasive (3-mm–diameter punch 
biopsies), it enables a direct study of small fibers that cannot be evaluated by NCV studies. 
Small-Fiber Neuropathies  
Symptoms are prominent in small-fiber neuropathies. Pain is of the C-fiber type. It is 
burning and superficial and is associated with allodynia (interpretation of all stimuli as 
painful). Patients have defective autonomic function with decreased sweating, dry skin, 
impaired vasomotion and blood flow, and cold feet. There are abnormalities in thresholds 
for warm thermal perception, neurovascular function, pain, quantitative sudorimetry, and 
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quantitative autonomic function tests. However, there is remarkable intactness of reflexes 
and motor strength. 
Clinical diagnosis is by reduced sensitivity to 1.0-g Semmes-Weinstein monofilament and 
pricking sensation using the Waardenberg wheel or similar instrument. These neuropathies 
are electrophysiologically silent. 
Large-Fiber Neuropathies  
Large fibers subserve motor function, vibration perception, position sense, and cold 
thermal perception. They tend to be affected first because of their length and the tendency 
in diabetes for nerves to die back. Because they are myelinated, they are the fibers 
represented in the EMG, and subclinical abnormalities in nerve function are readily 
detected.  
Clinical Presentation:  
Signs and symptoms of larg-fiber neuropathy include impaired vibration perception (often 
the first objective evidence) and position sense, depressed tendon reflexes, and sensory 
ataxia (waddling like a duck. Signs in the distal lower extremities include wasting of the 
small muscles of the feet, with hammertoes (intrinsic minus feet and hands) and weakness 
of the feet; shortening of the Achilles tendon with pes equinus, and increased blood flow 
(hot foot). Patients also have weakness in the hands. 
Most patients with DSPN, however, have a mixed variety of neuropathy, with both large 
and small nerve fiber damage. In the case of DSPN, a glove-and-stocking distribution of 
sensory loss is almost universal.[50] Early in the course of the neuropathic process, 
multifocal sensory loss also might be found. In some patients, severe distal muscle 
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weakness can accompany the sensory loss, resulting in an inability to stand on the toes or 
heels.  
 
Diagnosis of Peripheral Neuropathy: 
The diagnosis of diabetic neuropathy rests heavily on a careful history, for which a number 
of questionnaires have been developed by Young and colleagues,[14] Dyck,[68] Vinik,[69] and 
others.[70,71] 
 The initial neurologic evaluation should be directed toward detecting the specific part of 
the nervous system affected by diabetes. Bedside neurologic examination is quick and easy 
but provides nominal or ordinal measures and contains substantial inter-and intraindividual 
variation.  
The 1988 San Antonio conference on diabetic neuropathy and the 1992 conference of the 
American Academy of Neurology[29] recommended that at least one parameter from each 
of the following five categories are measured to classify diabetic neuropathy: symptom 
profiles, neurologic examination, QST, nerve conduction study, and autonomic function 
testing. A number of simple symptom screening questionnaires are available to record 
symptom quality and severity.  
A simplified neuropathy symptom score that was used in the European prevalence studies 
could also be useful in clinical practice.[14,72]  
The Michigan Neuropathy Screening Instrument (MNSI) is a 15-item questionnaire that 
can be administered to patients as a screening tool for neuropathy.[71] Other similar 
25 
 
symptom-scoring systems have also been described, such as the nerve impairment score of 
the lower limbs (NIS-LL).[73] 
Simple visual analogue or verbal descriptive scales may be used to follow patients' 
responses to treatment of their neuropathic symptoms.[ 74,75]  
An international group of experts in diabetic neuropathy held a consensus meeting to 
develop guidelines for managing diabetic peripheral neuropathy by the practicing 
clinician.[29] This clinical staging is in general agreement with that proposed by Dyck[76] for 
use in both clinical practice and epidemiologic studies or controlled clinical trials.  
The clinical no neuropathy is equivalent to Dyck's N0 (no objective evidence of diabetic 
neuropathy) or N1a (no symptoms or signs but neuropathic test abnormalities). Clinical 
neuropathy is equivalent to N1b (test abnormalities plus neuropathic impairment on 
neurologic exam), N2a (symptoms, signs, and test abnormalities), and N2b (N2a plus 
significant ankle dorsiflexor weakness). Late complications is equivalent to Dyck N3 
(disabling polyneuropathy). 
Peripheral Testing Devices  
The most widely used device in clinical practice is the Semmes-Weinstein 
monofilament.[77–79] The filament assesses pressure perception when gentle pressure is 
applied to the handle sufficient to buckle the nylon filament. It is also referred to as the 
5.07 monofilament because, during calibration, the filaments are calibrated to exert a force 
measured in grams that is 10 times the log of the force exerted at the tip: hence 5.07 exerts 
10 g force. A number of cross-sectional studies have assessed the sensitivity of the 10-g 
monofilament to identify feet at risk for ulceration. Sensitivities vary from 86% to 
100%,[80,81] although there is no consensus as to how many sites should be tested. 
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 The commonest algorithm recommends four sites per foot, generally the hallux and the 
first, third, and fifth metatarsal heads.[78] However, there is little advantage to multiple site 
assessments.[82] There is also no universal agreement about what constitutes an abnormal 
result (one, two, three, or four abnormal results from the sites tested). Despite these 
problems, the 10-g monofilament is widely used to clinically assess risk of foot ulceration.  
The graduated Rydel-Seifer tuning fork is used in some centers to assess neuropathy.[83,84] 
Liniger and colleagues reported that results with this instrument correlated well with other 
QST measures.[83] 
 The tactile circumferential discriminator assesses the perception of calibrated change in 
the circumference of a probe (a variation of two-point discrimination).[85] Vileikyte and 
coworkers[86] reported a 100% sensitivity in identifying patients at risk for foot 
ulceration.[86]  
Neuropen is a clinical device that assesses pain using a pin (Neurotip) at one end of the pen 
and a 10-g monofilament at the other end. This was shown to be a sensitive device for 
assessing nerve function when compared to the simplified neuropathy disability score.[620] 
Biopsy  
Biopsy of nerve tissue may be helpful for excluding other causes of neuropathy and in 
determining predominant pathologic changes in patients with complex clinical findings as 
a means of dictating choice of treatment.[53,87] Skin biopsy has some clinical advantages in 
diagnosing small-fiber neuropathies by quantification of PGP9.5 when all other measures 
are negative.[36,88] 
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Nerve Conduction Studies  
Whole nerve electrophysiologic procedures (e.g., NCV, F-waves, sensory amplitudes, 
motor amplitudes) have emerged as important methods of tracing the onset and progression 
of peripheral neuropathy.[89] 
These are objective, parametric, noninvasive and highly reliable measures. However, 
standard procedures, such as maximal NCV, reflect only a limited aspect of neural activity, 
and then only in a small subset of large-diameter and heavily myelinated axons. Even in 
large-diameter fibers, NCV is insensitive to many pathologic changes known to be 
associated with peripheral neuropathy. 
However, a key role for electrophysiologic assessment is to rule out other causes of 
neuropathy or to identify neuropathies superimposed on peripheral neuropathy.  
NCV is only gradually diminished by peripheral neuropathy, with estimates of a loss of 
approximately 0.5 m/sec per year.[89] 
In a 10-year natural history study of 133 patients with newly diagnosed T2DM, NCV 
deteriorated in all six nerve segments evaluated, but the largest deficit was 3.9 m/sec for 
the sural nerve (48.3 m/sec slowed to 44.4 m/sec); peroneal motor NCV was decreased by 
3.0 m/sec over the same period.[34]  
A similar slow rate of decline was demonstrated in the DCCT. A simple rule is that a 
decrease in HB A1c of one percentage point improves conduction velocity about 1.3 
m/sec.[90] There is, however, a strong correlation (r = 0.74; P < 0.001) between myelinated 
fiber density and whole nerve sural amplitude.[634] 
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Management:  
Once neuropathy is diagnosed, therapy can then be instituted with the goal of both 
ameliorating symptoms and preventing the progression of neuropathy. Successful 
management of these syndromes must be geared to individual pathogenic processes. 
Control of Hyperglycemia:  
Pirart[18] followed 4400 diabetic patients over 25 years and showed an increase in prevalence 
of clinically detectable diabetic neuropathy from 12% of patients at the time of diagnosis of 
diabetes to almost 50% after 25 years. The highest prevalence occurred in the people with 
poorest diabetes control. 
The DCCT Research Group[31] reported significant effects of intensive insulin therapy on 
prevention of neuropathy. The results of the DCCT study support the necessity for strict 
glycemic control, but the effect of insulin as a growth factor and immunomodulator, aside 
from its metabolic effects, must also be investigated. 
In the UKPDS, control of blood glucose was associated with improvement in vibration 
perception.[91] In the Steno trial,[92] a reduction of the odds ratio for the development of 
autonomic neuropathy to 0.32 was reported. This was a stepwise, progressive study that 
involved treating T2DM patients with hypotensive drugs, including ACE inhibitors, 
calcium-channel antagonists, hypoglycemic agents, aspirin, hypolipidemic agents, and 
antioxidants. These findings argue strongly for the multifactorial nature of neuropathy and 
for the need to address the multiple metabolic abnormalities. 
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Pharmacologic Therapy:  
Aldose Reductase Inhibitors:  
Aldose reductase inhibitors (ARIs) reduce the flux of glucose through the polyol pathway, 
inhibiting tissue accumulation of sorbitol and fructose and preventing reduction of redox 
potentials. 
In a placebo-controlled, double-blind study of tolrestat, 219 diabetic patients with 
symmetrical polyneuropathy, as defined by at least one pathologic cardiovascular reflex, 
were treated for 1 year.[92] Patients who received tolrestat showed significant improvement 
in autonomic function tests and in vibration perception, whereas placebo-treated patients 
showed deterioration in most of the parameters measured.[93] 
There is a dose-dependent improvement in nerve fiber density, particularly small 
unmyelinated nerve fibers, in a 12 month study of zenarestat.[94] This was accompanied by 
an increase in NCV, although the changes in NCV occurred at a dose of the drug that did 
not change the nerve fiber density.[94] Impaired cardiac ejection fractions can be improved 
with zopolrestat.[95] Clinical improvement has been reported for fidarestat and epalrestat in 
Japan.[96,97] 
α-Lipoic Acid:  
Lipoic acid (1,2-dithiolane-3-pentanoic acid), a derivative of octanoic acid, is present in 
food and is also synthesized by the liver. It is a natural cofactor in the pyruvate 
dehydrogenase complex, where it binds acyl groups and transfers them from one part of 
the complex to another. α-Lipoic acid, which also known as thioctic acid, has generated 
considerable interest as a thiol-replenishing and redox-modulating agent. It has been shown 
to be effective in ameliorating the somatic and autonomic neuropathies in diabetes.[98–100]  
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γ-Linolenic Acid:  
Linoleic acid, an essential fatty acid, is metabolized to dihomo-g-linolenic acid, which 
serves as an important constituent of neuronal membrane phospholipids and as a substrate 
for prostaglandin E formation, which appears to be important for preserving nerve blood 
flow. In diabetes, conversion of linoleic acid to γγlinolenic acid and subsequent 
metabolites is impaired, possibly contributing to the pathogenesis of diabetic 
neuropathy.[101]   
Protein Kinase C-β Inhibition:  
Neural vascular insufficiency has been proposed as a contributing factor to development of 
diabetic neuropathy.[102] PKC activation is a critical step in the pathway to diabetic 
microvascular complications[103] It is hyperactivated by hyperglycemia and disordered fatty 
acid metabolism, resulting in increased production of vasoconstrictive, angiogenic, and 
chemotactic cytokines including TGF-β, VEGF, endothelin, and ICAMs.  
Preliminary results of a multinational randomized, double-blind, placebo-controlled phase 
II trial showed a statistically significant improvement in symptoms, measured by the 
Neuropathy Total Symptom Score 6 (NTSS-6), in ruboxistaurin-treated neuropathy groups 
as compared with placebo.[104] The drug was well tolerated and there were few adverse 
events. 
Aminoguanidine: 
Animal studies using aminoguanidine, an inhibitor of the formation of AGEs, show 
improvement in nerve conduction velocity in streptozotocin-induced diabetic neuropathy 
in rats. Controlled clinical trials to determine its efficacy in humans[105,106] have been 
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discontinued because of toxicity. There are, however, successors to aminoguanidine that 
hold promise for this approach.[107] 
Neurotrophic Therapy:  
In a 15-center double-blind, placebo-controlled study of the safety and efficacy of rhNGF 
in 250 subjects with symptomatic small-fiber neuropathy,[108] rhNGF improved the 
neurologic impairment score of the lower limbs and improved small nerve fiber function 
cooling threshold (Aδ-fibers) and the ability to perceive heat pain (C-fiber) compared with 
placebo. These results were consistent with the postulated actions of NGF on TrkA 
receptors present on small-fiber neurons. 
 Results of these NGF studies were presented at the ADA meetings in June 1999.[109] 
Regrettably, rhNGF was not found to have beneficial effects over placebo. The reason for 
this dichotomy has not been resolved, but this has somewhat dampened the enthusiasm for 
growth factor therapy of diabetic neuropathy. 
Pain Control:  
Control of pain constitutes one of the most difficult management issues in diabetic 
neuropathy. In essence, simple measures are tried first. If no distinction is made for pain 
syndromes, then the number needed to treat (NNT) to reduce pain by 50% is 1.4 for 
optimal-dose tricyclic antidepressants, 1.9 for dextromethorphan, 3.3 for carbamazepine, 
3.4 for tramadol, 3.7 for gabapentin, 5.9 for capsaicin, 6.7 for selective serotonin reuptake 
inhibitors, and 10.0 for mexiletine.[110]  
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Insulin:  
Continuous intravenous insulin infusion without resort to blood glucose lowering may be 
useful in these patients. A response with reduction of pain usually occurs within 48 
hours,[111] and the insulin infusion can be discontinued. If this measure fails several 
medications are available that might abolish the pain. 
Nerve Blocking:  
Lidocaine given by slow infusion has been shown to provide relief of intractable pain for 3 
to 21 days. If successful, therapy can be continued with oral mexiletine. These compounds 
target the pain caused by hyperexcitability of superficial free nerve endings.[112] 
Tramadol and Dextromethorphan:  
Tramadol was shown to be better than placebo in a randomized, controlled trial[113] of only 
6 weeks' duration, but a subsequent follow-up study suggested that symptomatic relief 
could be maintained for at least 6 months.[114]Another spinal cord target for pain relief is 
the excitatory glutaminergic N-methyl-d-aspartate (NMDA) receptor. Blockade of NMDA 
receptors is believed to be one mechanism by which dextromethorphan exerts analgesic 
efficacy.[115]  
Antidepressants:  
Among the norepinephrine reuptake inhibitors, desipramine, amitriptyline, and imipramine 
have been shown to be of benefit.[116,117] 
Selective serotonin reuptake inhibitors (SSRIs) that have been used for neuropathic pain 
are paroxetine, fluoxetine, sertraline, and citalopram.  
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Antiepileptic Drugs:  
Anticonvulsants have stood the test of time in treatment of diabetic neuropathy.[118,119] 
Principal mechanisms of action include sodium channel blockade (felbamate, lamotrigine, 
oxcarbazepine, topiramate, zonisamide), potentiation of γ-aminobutyric acid (GABA) 
activity (tiagabine, topiramate), calcium-channel blockade (felbamate, lamotrigine, 
topiramate, zonisamide), antagonism of glutamate at NMDA receptors (felbamate) or α-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) (felbamate, 
topiramate).[120] 
Adjunct Management and Treatment of Complications:  
Patients can benefit from high-intensity strength training by increasing muscle strength and 
improving coordination and balance, thus reducing fall and fracture risks.[121,122] In 
addition, options to prevent and correct foot deformities are available, including orthotics, 
surgery, and reconstruction. 
Prevention:  
Basic management of small-fiber neuropathies by the patient should be encouraged. These 
include foot protection and ulcer prevention by wearing padded socks; daily foot 
inspection using a mirror to examine the soles of the feet; selection of proper footwear; 
scrutiny of shoes for the presence of foreign objects that lodge themselves in closed shoes; 
and avoidance of sun-heated surfaces, hot bathwater, and sleeping with feet in front of 
fireplaces or heaters.  
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Stimulation:  
Transcutaneous nerve stimulation (electrotherapy) occasionally is helpful and certainly 
represents one of the more benign therapies for painful neuropathy.[123]   However, this 
cannot be generally recommended except in very resistant cases because it is invasive, 
expensive, and unproven in controlled studies.  
Autonomic Neuropathies:  
Diabetic autonomic neuropathy can cause dysfunction of every part of the body. Diabetic 
autonomic neuropathy often goes completely unrecognized by patient and physician alike 
because of its insidious onset and protean multiple organ involvement. The organ systems 
that most often exhibit prominent clinical autonomic signs and symptoms in diabetes 
include the ocular pupil, sweat glands, genitourinary system, gastrointestinal system, 
adrenal medullary system, and cardiovascular system.  
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DIAGNOSTIC TESTS OF CARDIOVASCULAR AUTONOMIC NEUROPATHY 
RESTING HEART RATE 
Rate >100 beats/min is abnormal. 
BEAT-TO-BEAT HEART RATE VARIATION[*] 
With the patient at rest and supine (no overnight coffee or hypoglycemic episodes), breathing 
6 breaths/min, heart rate monitored by ECG or Anscore device, a difference in heart rate of 
>15 beats/min is normal and <10 beats/min is abnormal, R-R inspiration to R-R expiration 
>1.17. All indices of HRV are age-dependent.[†] 
HEART RATE RESPONSE TO STANDING[*] 
During continuous ECG monitoring, the R-R interval is measured at beats 15 and 30 after 
standing. Normally, a tachycardia is followed by reflex bradycardia. The 30 : 15 ratio is 
normally >1.03. 
HEART RATE RESPONSE TO VALSALVA MANEUVER[*] 
The subject forcibly exhales into the mouthpiece of a manometer to 40 mm Hg for 15 
seconds during ECG monitoring. Healthy subjects develop tachycardia and peripheral 
vasoconstriction during strain and an overshoot bradycardia and rise in blood pressure with 
release. The ratio of longest R-R shortest R-R should be >1.2. 
SYSTOLIC BLOOD PRESSURE RESPONSE TO STANDING 
Systolic blood pressure is measured in the supine subject. The patient stands and the systolic 
blood pressure is measured after 2 min. Normal response is a fall of <10 mm Hg, borderline 
is a fall of 10-29 mm Hg, and abnormal is a fall of >30 mm Hg with symptoms. 
DIASTOLIC BLOOD PRESSURE RESPONSE TO ISOMETRIC EXERCISE 
The subject squeezes a handgrip dynamometer to establish a maximum. Grip is then squeezed 
at 30% maximum for 5 min. The normal response for diastolic blood pressure is a rise of >16 
mm Hg in the other arm. 
ECG QT/QTC INTERVALS 
The QTc (corrected QT intevval on EKG) should be <440 ms. 
SPECTRAL ANALYSIS 
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    HF peak ↓ (parasympathetic dysfunction) 
    LF peak ↓ (sympathetic dysfunction) 
    LH/HF ratio ↓ (sympathetic imbalance) 
    VLF peak ↓ (sympathetic dysfunction) 
 
NEUROVASCULAR FLOW 
Noninvasive laser Doppler measures peripheral sympathetic responses to nociception. 
ECG, electrocardiogram; HF, high frequency; HRV, heart rate variation; LF, low frequency; 
VLF, very low frequency. 
 
* These can now be performed quickly (<15 min) in the practitioner's office, with a central 
reference laboratory providing quality control and normative values. These are now readily 
available in most cardiologist's practice. 
† Lowest normal value of E/I ratio: Age 20-24 yr: 1.17; 25-29 yr: 1.15; 30-34 yr: 1.13; 35-30 
yr: 1.12; 40-44 yr: 1.10; 45-49 yr: 1.08; 50-54 yr: 1.07; 55-59 yr: 1.06; 60-64 yr: 1.04; 65-
69 yr: 1.03; 70-75 yr: 1.02. 
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Management  
Postural Hypotension  
The syndrome of postural hypotension is posture-related dizziness and syncope. Patients 
who have T2DM and orthostatic hypotension are hypovolemic and have sympathoadrenal 
insufficiency; both factors contribute to the pathogenesis of orthostatic hypotension.[124]  
Supportive Garments  
Whenever possible, attempts should be made to increase venous return from the periphery 
using total body stockingsPatients should be instructed to put these garments on while 
lying down and to not remove them until returning to the supine position. 
Drug Therapy  
Some patients with postural hypotension benefit from treatment with 9-
fluorohydrocortisone.  Metoclopromide may be helpful in patients with dopamine excess 
or increased sensitivity to dopaminergic stimulation. Patients with α2-adrenergic receptor 
excess might respond to the α2-antagonist yohimbine. Those few patients in whom β-
receptors are increased may be helped with propranolol. α2-Adrenergic receptor deficiency 
can be treated with the α2-agonist clonidine, which in this setting can paradoxically 
increase BP.  
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MATERIALS AND METHODS    : 
                                                         The study was conducted in Department of General 
Medicine, Thanjavur  Medical College from December 2008 to May 2010.  
                              It was a cross-sectional study involving one hundred diabetic patients 
attending the diabetic clinics. They were chosen by stratified randomized sampling. They 
were categorized into two groups of 50 each based on comprehensive neurological 
examination (Michigan Neuropathic Diabetic Scoring – MNDS and monofilament testing).  
           Group 1 included type 2 diabetes mellitus patients without peripheral neuropathy.  
           Group 2 included type 2 diabetes mellitus patients with peripheral neuropathy. 
                                MNDS gives the score in the range of 0 – 8, based on evaluation of 4 
different factors in each link. These factors are appearance of foot (dry skin, callus, 
deformity, fissure, and infection), presence of ulcer, Achilles tendon reflex, and vibration 
perception of the great toe with 128Hz tuning fork. A neuropathic foot scores 3 or higher, 
while a normal foot scores 2.5 or lower. This scoring system has the sensitivity and 
specificity of 95%. 
                                 Neuropathy was also defined as the loss of protective sensation 
determined through application of the 10-g Semmes-Weinstein monofilament wire system.  
INCLUSION CRITERIA: 
 Type 2 diabetics between 20 and 80 years of age. 
 Duration of diabetes more than 4 years 
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EXCLUSION CRITERIA 
 Serum creatinine more than 2 mg/dl 
 Pregnant women 
 DM of  specific etiology 
 Diabetic emergencies 
 Medications known to cause peripheral neuropathy 
 Alcoholism 
 Hansen’s disease 
 AIDS 
 Hypothyroidism 
 Stroke  
 B12 deficiency 
 Loss of dorsalis pedis pulsation 
 
 PROCEDURE: 
                                       After written informed consent, detailed information on patient’s 
age, sex, duration of diabetes, presence of hypertension, Coronary artery disease (CAD), 
smoking, were obtained. Body mass index and presence or absence of postural hypotension 
was recorded. The following investigations were carried out: HbA1c(%), fasting blood sugar, 
post prandial blood sugar, lipid profile, spot test for albuminuria and micro-albuminuria, 
blood urea and serum creatinine, hemoglobin (gm/dl). 
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Parameters studied: 
 Duration of diabetes  
 Glycemic control 
 Lipid profile 
 Albuminuria 
 Micro-albuminuria 
 Systemic hypertension 
 CAD 
 Smoking 
 BMI 
 Height  
                      
Glycemic control was classified according to HbA1c (%), fasting and postprandial blood 
sugar values.HbA1c values were measured by spectro – photometry. Patients with blood 
pressure (BP) more than or equal to 140/90 mm Hg were considered hypertensive. 
Microalbuminuria was measures by latex turbidimetry. Microalbuminuria is defined as 
excretion rate of albumin between 20 and 200 mgs/L and macroalbuminuria is  measured by 
protein dip stick . Enzymatic colorimetric method was used for measuring serum cholesterol, 
Triglycerides, HDL , LDL levels. 
 Data was analysed using SPSS 17 software after matching for age and sex.  
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OBSERVATION: 
DURATION OF DIABETES 
 
SAMPLE GROUP 
 
              MEAN 
 
 STANDARD        
DEVIATION 
 
      T - value 
                                                 
     p- value 
WITH 
PERIPHERAL 
NEUROPATHY 
              8.38              4.54            
         1.984 
 
     0.046 
WITHOUT 
PERIPHERAL 
NEUROPATHY 
             6.44              4.71 
 
 
 
The mean duration of treatment for diabetes mellitus in patients with peripheral 
neuropathy is 8.38 years whereas; in patients without peripheral neuropathy is 6.44 years. 
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FASTING BLOOD SUGAR: 
  
 
SAMPLE GROUP 
 
              MEAN 
 
 STANDARD        
DEVIATION 
 
      T - value 
                                                 
     p- value 
WITH 
PERIPHERAL 
NEUROPATHY 
             164.34              52.574            
        1.984 
 
      0.0444 
WITHOUT 
PERIPHERAL 
NEUROPATHY 
             143.34          48.304     
 
 
 
The mean fasting blood sugar value in patients with peripheral neuropathy is 164.34mgs/dl. 
In patients without peripheral neuropathy, the mean value is 143.34mgs/dl. 
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HBAIC: 
 
 
SAMPLE GROUP 
 
              MEAN 
 
 STANDARD        
DEVIATION 
 
      T - value 
                                                 
     p- value 
WITH 
PERIPHERAL 
NEUROPATHY 
              9.07             2.61                
         2.230 
 
      0.0280 
WITHOUT 
PERIPHERAL 
NEUROPATHY 
             7.92            2.54    
 
  
The mean HbA1c value in patients with peripheral neuropathy is 9.07%. In patients without 
peripheral neuropathy is 7.92%.  
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TOTAL CHOLESTEROL: 
 
 
 
SAMPLE GROUP 
 
              MEAN 
 
 STANDARD        
DEVIATION 
 
      T - value 
                                                 
     p- value 
WITH 
PERIPHERAL 
NEUROPATHY 
            205.9             25.879             
        0.755 
 
 0.452      
WITHOUT 
PERIPHERAL 
NEUROPATHY 
             202.08            25.508 
 
 
The mean Total cholesterol value in patients with peripheral neuropathy is 205.9mgs/dl. In 
patients without peripheral neuropathy is 202.08mgs/dl. There is no significant difference in 
patients with and without peripheral neuropathy. 
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SERUM TRIGLYCERIDES: 
 
SAMPLE GROUP 
 
              MEAN 
 
 STANDARD        
DEVIATION 
 
      T - value 
                                                 
     p- value 
WITH 
PERIPHERAL 
NEUROPATHY 
            187.5           29.259            
       2.6573    
 
      0.0092 
WITHOUT 
PERIPHERAL 
NEUROPATHY 
            173.46           23.231   
 
  
  
 
 
The mean value of triglycerides in patient with peripheral neuropathy is 187.5mgs/dl. The 
mean value of triglycerides in patients without peripheral neuropathy is 173.46mgs/dl. This 
difference is statistically significant. 
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HDL, LDL and VLDL: 
HDL: 
 
LDL: 
 
 
 
 
 
 
VLDL: 
 
 
 
 
 
The mean values of HDL, LDL, and VLDL were 56.78mgs/dl,111.62mgs/dl and 36.88mgs/dl 
respectively in patients with diabetic peripheral neuropathy. In patients without peripheral 
neuropathy the mean HDL,LDL and VLDL were  55.549 mgs/dl, 111.34mgs/dl, 35.18mgs/dl 
respectively. The observed differences were not statistically significant. 
 
 
SAMPLE GROUP 
  Mean 
(mgs/d
l) 
Std. 
Deviation 
     T- 
VALUE 
 
P-VALUE 
 WITH DPN 56.78 3.489       
       
1.6948 
         
     0.0933 
WITHOUT DPN 55.549 3.769   
 
 
SAMPLE GROUP 
  Mean 
(mgs/d
l) 
Std. 
Deviation 
     T- 
VALUE 
 
P-VALUE 
 WITH DPN 111.62 22.425       
       
0.0617 
         
     0.9509 
WITHOUT DPN 111.34 22.931   
 
 
SAMPLE GROUP 
  Mean 
(mgs/d
l) 
Std. 
Deviation 
     T- 
VALUE 
 
P-VALUE 
 WITH DPN 36.88 5.7627       
1.6661 
         
     0.0989 
WITHOUT DPN 35.18 4.341   
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SYSTEMIC HYPERTENSION: 
                
           SAMPLE GROUP 
STSTEMIC 
HYPERTENSION 
     CHI SQUARE TEST 
            P-VALUE 
no yes 
With Peripheral Neuropathy 
Without Peripheral Neuropathy 
23 27             0.0142 
 36 14 
 
  
54% of patients with peripheral neuropathy were known hypertensive but among patients 
without peripheral neuropathy , the prevalence was only 28%. 
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MACROALBUMINURIA: 
                
           SAMPLE GROUP 
ALBUMINURIA      CHI SQUARE TEST 
            P-VALUE 
no yes 
With Peripheral Neuropathy 
 
Without Peripheral Neuropathy 
35 15              0.0228 
 45 5 
 
 
 
 
Among patients with peripheral neuropathy, 30% had macroalbuminuria. In patients 
without peripheral neuropathy only 10% had macroalbuminuria. 
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MICROALBUMINURIA: 
 
 
 
 
 
 
The mean microalbuminuria level in patients with diabetic peripheral neuropathy is 66.60 
mgs/dl. In patients without diabetic peripheral neuropathy the mean value is 41.80 mgs/dl. 
This difference is statistically significant. 
 
0
10
20
30
40
50
60
70
WITH DPN
WITHOUT DPN
M
IC
RO
A
LB
U
M
IN
U
RI
A
 (m
gs
/d
l)
SAMPLE POPULATION
microalbuminuria
  
 
SAMPLE GROUP N 
Mean 
(mgs/
dl) 
Std. 
Deviation     T- Value 
 
P-Value 
 WITH DPN 35 66.60 44.504      3.2407         0.0018 
WITHOUT DPN 45 41.80 22.660   
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CORONARY ARTERY HEART DISEASE: 
 
            
            SAMPLE GROUP 
 
CAHD  
           Chi- 
square 
 
              p-value 
no yes 
WITH PERIPHERAL 
NEUROPATHY 
WITHOUT PERIPHERAL 
NEUROPATHY 
 
 
 36      14          5.263                 0.022 
 45   5  
 
 
 
 
28% of patients with peripheral neuropathy had CAHD. In patients without peripheral 
neuropathy, only 10% of patients had CAHD.  
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SMOKING: 
 
 
            
            SAMPLE GROUP 
 
SMOKER  
           Chi- 
square 
 
              p-value 
no yes 
WITH PERIPHERAL 
NEUROPATHY 
WITHOUT PERIPHERAL 
NEUROPATHY 
 
 
 34       16          4.574                 0.032 
 43   7  
 
 
 
 
 
 
 
 
32% of patients with diabetic peripheral neuropathy were smokers. Among patients without 
peripheral neuropathy, 14% of patients were non smokers. 
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POSTURAL HYPOTENSION: 
 
 
 
 
 
 
 
 
   
 
 
 
Among patients with peripheral neuropathy, 28% of them had postural hypotension. Among 
patients without peripheral neuropathy, only 12% of patients were having a postural fall in 
blood pressure. However this difference is not statistically significant. 
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POSTURAL 
HYPOTENSION 
 
              p-value 
no yes 
WITH PERIPHERAL 
NEUROPATHY 
WITHOUT PERIPHERAL 
NEUROPATHY 
 
 
 36       14                      0.0784 
 44   6  
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BODY MASS INDEX: 
 
 
 
 
 
 
        SAMPLE GROUP 
   
  
Mean 
 
Std. 
Deviation 
     T- 
VALUE 
 
P-VALUE 
 WITH DPN 25.28 4.025 
 
      
      3.5974 
         
          
0.0005 
WITHOUT DPN 22.7 3.085   
 
 
 
The mean BMI of patients with diabetic neuropathy is 25.28. in patients without diabetic 
peripheral neuropathy, the mean BMI is 22.7. This difference is statistically significant with a 
p-value of 0.0005. 
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HEIGHT: 
 
 
 
 
 
 
In patients without peripheral neuropathy, the mean height was 1.585m. In patients with 
peripheral neuropathy, the mean height was 1.5788m. This difference is not statistically 
significant. 
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SAMPLE GROUP 
  
Mean 
   (m) 
Std. 
Deviation 
     T- 
VALUE 
 
P-VALUE 
 WITH DPN 1.578
8 
0.088  
     0.3282 
         
      0.7435 
WITHOUT DPN 1.585 0.1005   
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SYSTOLIC BLOOD PRESSURE: 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mean systolic blood pressure in patients without peripheral neuropathy is 144 mm hg. In 
patients without peripheral neuropathy the mean systolic blood pressure is 138 mmhg. This 
difference is not statistically significant.    
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SAMPLE GROUP 
  Mean 
 (mm  
hg) 
Std. 
Deviation 
     T- 
VALUE 
 
P-VALUE 
 WITH DPN 144 24  
     1.6254 
         
      o.1073 
WITHOUT DPN 138 20   
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DIASTOLIC BLOOD PRESSURE: 
  
 
 
 
 
 
 
 
The mean diastolic blood pressure in patients with peripheral neuropathy is 90 mmhg. In 
patients without neuropathy , the mean diastolic blood pressure is 86 mmhg. This difference 
is not statistically significant. 
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SAMPLE GROUP 
  Mean 
 (mm  
hg) 
Std. 
Deviation 
     T- 
VALUE 
 
P-VALUE 
 WITH DPN     90 15  
     1.3323 
         
      0.1858 
WITHOUT DPN      86          13   
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DISCUSSION: 
 
Diabetic peripheral neuropathy is a common complication of diabetes mellitus with high 
morbidity and impairment of quality of life. This hospital based, cross-sectional study of risk 
factors for diabetic peripheral neuropathy conducted in diabetology out patient department, 
thanjavur medical college hospital during the period of March 2009 to February 2010 found 
several factors which are significantly associated with an increased risk of peripheral 
neuropathy which are discussed further. 
 
DURATION OF DIABETES: 
 
This study shows a significant relationship between duration of diabetes and peripheral 
neuropathy. The mean duration of diabetes mellitus in patients with diabetic neuropathy is 
8.38 years in this study. 
 In Ashok study [125] , diabetic peripheral neuropathy showed significant relationship with age, 
duration of diabetes mellitus. This was a cross-sectional study comprising 1000 consecutive 
type 2 DM patients attending MV Diabetes speciality centre in South India. In this study 
mean duration of diabetes in patients with diabetic peripheral neuropathy was 12 years.  
This result is in concordance with Tesfaye S et al study [126] , J.E.Shaw et al study [127] , Booya 
F et al study [128] , Barbosa A P et al study [129] , and Ugoya S Oet al study [130] . 
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FASTING BLOOD SUGAR: 
This study shows a significant association between fasting blood sugar values and diabetic 
peripheral neuropathy. Mean FBS values in patients with peripheral neuropathy is 164.34 
mg/dl.  
Booya Fet al study [128] showed no significant relationship between FBS values and 
peripheral neuropathy. Similarly, Ashok et al study also showed no significant relationship 
between the peripheral neuropathy and FBS values. Ugoya S Oet al study [130] showed a 
significant association between FPG values and peripheral neuropathy. This was a cross- 
sectional study involving 120 diabetic subjects to determine the risk factors associated with 
diabetic peripheral neuropathy in Jos University Teaching Hospital, Nigeria. 
 This result is also in concordance with kumamoto study [131] which concluded that intensive 
glycemic control would have a beneficial effect on both somatic and autonomic nerve 
functions. 
HbA1c:  
High HbA1c levels were associated with peripheral neuropathy. The mean HbA1c level in 
the present study is 9.07%.   
According to UKPDS [132], each 1% reduction in HbA1c levels was associated with a 37% 
decrease in risk of microvascular complications. EDIC study [133] concluded that the incident 
and prevalent neuropathy at EDIC 13 to 14 years were influenced by mean A1c levels 
confirming that poor glycemic control is a significant and robust predictor of neuropathy.  
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According to Bin lu et al study [134] , which was a cross-sectional risk factor study involving 
435 diabetic patients in Shanghai town to evaluate the prevalence of diabetic complications. 
The mean HbA1c value in patients with diabetic peripheral neuropathy was 7.33%. The study 
concluded that HbA1c was a significant risk determinant for diabetic peripheral neuropathy.  
The diabetes control and complications trial (DCCT) [135] , has established that lowering of 
HbA1c in patients with IDDM was associated with a reduction in subsequent development of 
clinical neuropathy.  
According to Kumamoto study [131] , the glycemic threshold to prevent the onset and 
progression of diabetic microvascular complications are as follows, HbA1c < 6.5%, FBS < 
110 mgs/dl and 2hr post prandial blood glucose concentration < 180 mgs/dl. Ashok et al 
study [118] did not show any significant association of HbA1c levels with peripheral 
neuropathy.  
TOTAL CHOLESTEROL:   
The study did not show a significant relationship of total cholesterol with diabetic peripheral 
neuropathy. The mean cholesterol level in patients with diabetic peripheral neuropathy is 
205.9mgs/dl. Tesfaye S et al study [126]  involved 1172 patients with type 1 DM from 31 
centres participating in the EURODIAB diabetes prospective complications study and were 
studied for risk factors in the development of distal symmetric polyneuropathy. According to 
this study, there was a significant association of total cholesterol level with the occurrence of 
peripheral neuropathy. Janghorbani M et al study [137] was a cross-sectional risk factor study 
for diabetic peripheral neuropathy involving 810 type 2 DM patients. The study did not 
reveal any significant association of total cholesterol levels with diabetic peripheral 
nephropathy. Similarly.Ugoya S O et al study[130] did not reveal any significant association of 
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total cholesterol level with peripheral neuropathy. Ashok et al study [125] also did not show 
any significant relationship between total cholesterol and peripheral neuropathy. 
SERUM TRIGLYCERIDES: 
The study revealed significant association of mean serum triglyceride levels with peripheral 
neuropathy. The mean serum triglyceride level in the study is 187.5mgs/dl. Tesfaye S et al 
study [136] showed a significant relationship of serum triglyceride levels with peripheral 
neuropathy. Ashok et al study [125] also reveals significant relation between serum triglyceride 
level and diabetic peripheral neuropathy.In Wiggin T D et al study [138] data obtained from 
two identical double blind placebo controlled ,multicentric,52-week clinical diabetic 
neuropathy trials were analysed. In this cohort of participants with mild to moderate diabetic 
neuropathy, elevated triglycerides correlated with MFD loss independent of disease duration, 
diabetes control, or other variables. This hypothesis may explain the earlier incidence of 
diabetic neuropathy in individuals with type 2 diabetes mellitus compared with individuals 
with type 1 diabetes mellitus. Dyslipidemia develops later in course of type 1 diabetes and the 
delayed development of an abnormal lipid profile coincides with delayed onset and 
progression of diabetic neuropathy.[139,140] The correlation between triglycerides and diabetic 
neuropathy progression suggests that hyperglycaemia and aberrant glucose metabolism are 
not the only factors contributing to nerve damage. Triglycerides are components of HDL, 
LDL, and VLDL lipid transporters. When measured in serum, free triglycerides are a 
surrogate marker of endogenous lipid transport pathway activity. Correction of dyslipidemia 
with statins has an ameliorative effect on the development and progression of diabetic 
neuropathy [134,135] . 
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HDL, LDL AND VLDL: 
The study did not reveal an association between HDL, LDL and VLDL levels and peripheral 
neuropathy. Tesfaye S et al study [136] showed a reduced level of HDL levels in patients with 
peripheral neuropathy. Schwann cell lipid metabolism has been found to be abnormal.  
Maser RE, Steenkiste AR, Dorman JS et al study[143] has also reported a significant 
association of diabetic peripheral neuropathy with lower HDL cholesterol levels. This may 
reflect a blood marker of the pathological changes in the myelin structure of nerve. 
 Ashok et al study[125] does not show any significant association between HDL and diabetic 
peripheral neuropathy. Elliot J et al study[144] does not show a statistically significant 
association of HDL levels with the incidence of abnormal  VPT after adjustment  for A1c  
and duration of diabetes.  
Our result is in concordance with Ugoya S O et al study [130] . The result is also in 
concordance with Jonghorbani M et al study [137] , which was a cross sectional risk factor 
study from Isfahm endocrinology and metabolism research centre outpatient clinics, Iran. In 
this study, 810 patients with type 2 diabetes mellitus were examined. Part of examination 
included an assessment of neurological function including neuropathic symptoms, physical 
signs and nerve conduction velocity.  
In Tesfaye S et al study[136] ,LDL cholesterol levels showed a significant association in 
patients with diabetic peripheral neuropathy. According to Elliot J et al study [144] , LDL 
cholesterol levels showed a significant relationship with the incidence of abnormal VPT after 
adjustment for HbA1c  and duration of diabetes. The Fremantle diabetes study [145] stated that 
therapy with a statin or a fibrate may protect against the development of diabetic peripheral 
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neuropathy but there is need for additional confirmatory evidence, preferably randomised 
clinical trials. 
SYSTEMIC HYPERTENSION: 
Prevalence of systemic hypertension in patients with peripheral neuropathy is 54%. The 
association between systemic hypertension and diabetic peripheral neuropathy is statistically 
different. 
 The result is in concordance with Tesfaye S et al study [136] . Elliott J et al study[144] showed a 
significant relationship between systemic hypertension and diabetic peripheral neuropathy. 
According to UKPDS[146] , the surrogate indices of neuropathy and autonomic neuropathy 
were not significantly different between patients with and without diabetic peripheral 
neuropathy. 
 Booya F et al study[128] did not show any significant association between systemic 
hypertension and peripheral neuropathy. MaserRE, Steenkisk AR, Dorman JS et al study [143] 
has reported a significant association between systemic hypertension and diabetic peripheral 
neuropathy.  
Harris M,R ,C.Cowie et al study[147] shows hypertension predisposes to symptoms of sensory 
neuropathy. 
SYSTOLIC BLOOD PRESSURE: 
The mean systolic blood pressure in patients with diabetic peripheral neuropathy is 
144mmhg. There is no significant difference between mean systolic blood pressure in 
patients with and without peripheral neuropathy in this study. 
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 Ugoya S O et al study [130] showed a significant relationship between systolic blood pressure 
and diabetic peripheral neuropathy. Janghorbani M et al study [137] showed a significant 
association between systolic blood pressure and diabetic peripheral neuropathy. 
Cohen J A et al study [148] study was under taken to identify risk factors for the development 
of diabetic sensory peripheral neuropathy and diabetic autonomic neuropathy, along with 
their relationship to other diabetic complications, in a representative diabetic population.  
The Appropriate Blood pressure Control in Diabetes [ABCD] Trial [149] is comprised of 949 
NIDDM patients. A wide range of diabetic sensory peripheral neuropathy risk factors and 
diabetic complications have been investigated. In this trial systolic blood pressure was 
significantly associated with diabetic peripheral neuropathy. Ashok et al study [125] showed a 
significant association between systolic blood pressure and diabetic peripheral neuropathy. 
DIASTOLIC BLOOD PRESSURE: 
In this study, diastolic blood pressure did not reveal any significant association with diabetic 
sensory neuropathy. Ugoya S Oet al [130]study showed a significant relationship between 
diastolic blood pressure  and peripheral neuropathy.  
Cohen JA et al study [148] did not show a significant association between diastolic blood 
pressure and diabetic peripheral neuropathy. Janghorbani M et al study [137] did not show a 
significant association prevalence of peripheral neuropathy and diastolic blood pressure. 
 S Tesfaye S et al study [136] shows significant trends of increasing prevalence of diabetic 
peripheral neuropathy with increasing diastolic blood pressure. Ashok et al study[125] did not 
show a significant association between diastolic blood pressure and peripheral neuropathy 
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MICROALBUMINURIA: 
The study shows significant association between microalbuminuria  and the prevalence of 
peripheral neuropathy. The mean microalbuminuria value in peripheral neuropathy patients is 
found to be 66.6mgs/dl. 
 In Lluch et al study [150] , which was a cross-sectional study involving 100 type 1 DM 
patients. Patients were studied for risk factors contributing to peripheral neuropathy and 
autonomic neuropathy. In Tesfaye S et al study[136] , the presence of microalbuminuria was a 
significant predictor of peripheral neuropathy. Elliott J et al study [144] showed a significant 
association between the incidence of abnormal VPT and after adjustment for A1c and 
duration of diabetes and microalbuminuria. 
 S.Savage et al study[151] was a large population was a large population study of 947 NIDDM 
patients living predominantly in a metropolitan area. This study shows that urine albumin 
excretion is significantly associated with neuropathy. This suggests that UAE may be more 
than an indicator of renal disease in NIDDM patients and in fact, may reflect a state of 
generalised vascular damage occurring throughout the body.  
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MACROALBUMINURIA:         
In this study 30% of patients with DPN had macroalbuminuria. The study shows a significant 
association between macroalbuminuria and DPN. Elliott J et al study[144] shows a significant 
association between the incidence of abnormal VPT and macroalbuminuria after adjustment 
for A1c and duration of diabetes.  
Solomon Tesfaye S et al study [136] shows significant association between newly diagnosed 
neuropathy and macroalbuminuria with an odds ratio of 1.48. In EURODIAB IDDM 
complications study[126] , multiple logistic regression analysis of DPN shows 
macroalbuminuria as a significant risk factor.  
Coppini D V et al study[152] study did not show a  significant association between prevalence 
of DPN and macroalbuminuria. J.E.Shaw et al study [127] showed a significant association 
between macroalbuminuria and DPN.  
Bin Lu et al study[134] showed that the percentage of macroalbuminuria in DPN group (9.0%) 
was significantly higher than that in the non – DPN group (1.8%).  J.E.Shaw et al study[127] 
found that a significant number of patients with diabetic nephropathy did not have peripheral 
neuropathy. 
SMOKING: 
This study shows smoking has a significant association with peripheral neuropathy. In 
Mitchell B D et al study[153] , it is shown that the risk for neuropathy was 3 times higher in 
smoking type 1 DM patients than in non-smokers. Smoking was not related to neuropathy in 
type 2 DM patients. 
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 Christen WG et al study[154] in young IDDM patients, it was shown that apart from glycemic 
control, cigarette smoking may be an independent risk factor for progression of distal sensory 
neuropathy. In Masser RE et al [143] and Reichard P et al studies [155] , in type 1DM patients 
have confirmed the roles of glycemic control as well as smoking habits for the development 
of clinical neuropathy. 
 In Maser RE et al study[143] smoking status was found to be significantly associated with 
neuropathy in the models for > or = 18 yr old group and > or = 30 year old group. In Mitchell 
B Det al study [146] , cigarette smoking was significantly associated with DPN. According to 
Harris M et al study[147], height was not a significant risk determinant of peripheral 
neuropathy.  
According to A.I.Alder et al study [156] ,  neuropathy was less common in current smokers 
than subjects not currently smoking. In Janghorbani M et al study [137] smoking was not 
related to prevalence of sensory neuropathy. According to Tesfaye S et al study [136] cigarette 
smoking has been associated with peripheral neuropathy. K.Kasim et al study[157] was a 
cross-sectional study conducted in Al-Azhar University hospitals, Cairo, Egypt, recruited 300 
patients with type 2 DM patients who are attending diabetic clinics in the studied hospital 
from Oct 2005 through Jan 2006, showed no significant association between smoking and 
peripheral neuropathy. Elliott J et al study [144] shows significant association between and 
DPN. In  EURODIAB IDDM complications study [126] , smoking was significantly associated 
with the prevalence of DPN.  
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CORONARY ARTERY HEART DISEASE:           
The study showed a significant association between the history of CAHD and prevalence of 
DPN. In Ashok et al study[125] showed a good correlation between history of CAHD and 
prevalence of DPN.  
In EURODIAB IDDM complications study[126] , significant association was found between 
the prevalence of DPN and the presence of cardiovascular disease. Owlabi MO et al study 
[158] shows aggregate cardiovascular load was a stronger statistical correlate and predictor of 
clinically evident DPN.  
 According to Barbosa A P et al study [129], CAHD is significantly associated with DPN. 
Elliott J et al study [137] the presence of cardiovascular disease at baseline seem to predict the 
development of abnormal VPT. In Davis T M E et al study[145], the presence of CVD at 
baseline is associated with the prevalence of DPN. In Janghorbani M et al study [137], 
significant number of patients with peripheral neuropathy had CAHD. According to Tesfaye 
S et al study [136] the incidence of neuropathy is associated with CAHD.   
 
 BMI: 
The study shows statistically significant association between obesity and DPN. According to 
Coppini D V et al study [152] , higher BMI was associated with prevalence of DPN. In 
K.Kasim et al study [157] risk was reduced among married and obese patients. In Bruce SGet 
al study [159] increased BMI levels are significantly associated with the prevalence of DPN. 
 In Janghorbani M et al study[137] , BMI levels are not significantly associated with DPN. 
According to Ugoya S Oet al study[130], BMI levels are not significantly associated with DPN. 
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In Tesfaye S et al study[136], after adjustment of HbA1c and duration of diabetes, found that 
higher levels of BMI were significantly associated with the cumulative incidence of 
neuropathy. 
 In Bin Lu et al study[134], the DPN patients were older and had higher BMI when compared 
with patients without neuropathy. 
HEIGHT:     
In this study there was no significant association between patients with and without 
peripheral neuropathy. The mean height of patients with peripheral neuropathy is 1.57 
metres. J.E.Shaw et al study [127],,shows a significant association between height and DPN. 
M.T.Gadia et al study[160] shows significant relationship between height and DPN. Tesfaye S 
et al study [136] showed significant trends of increasing prevalence of diabetic peripheral 
neuropathywere only observed with increasing height. Elliott J et al study[144] ,shows 
association between the incidence of abnormal VPT and height after adjustment for HbAic 
and duration of diabetes. Alder AI et al study [156] shows significant difference in height 
between patients with and without peripheral neuropathy. Janghorbani M et al study [137] 
didnot show significant association between height and DPN.  Tesfaye S et al study [136] did 
not show any significant association between height and DPN.  
Davis T M E et al study [142] did not show any significant association between height and 
DPN.  Sosenko JM et al study[161] showed significant increased incidence of DPN in taller 
patients.  
Lawrence .R .Robinson et al study [162]supports the hypothesis that height is an important risk 
factor for polyneuropathy in diabetic subjects.   
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POSTURAL HYPOTENSION: 
Postural hypotension was measured to assess the integrity of autonomic nercous system. This 
study shows a significant association between postural hypotension and DPN.  
Ugoya S Oet al study [130] shows a significant association between autonomic neuropathy and 
DPN.  Elliott J et al study[144] shows a significant association between cardiac autonomic 
neuropathy and DPN. 
 Lluch I et al study [150] was a cross-sectional study involving 100 type 1 DM patients. This 
study concluded that cardiovascular autonomic neuropathy is frequent in type 1 DM patients, 
furthermore, prevalence increases with existence of peripheral neuropathy and duration of 
diabetes. 
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SUMMARY: 
1. One hundred patients with type 2 diabetes were included in the study. 
2.  Patients were randomised to two groups of 50 each. Group 1 included patients without 
neuropathy and group 2 included patients with neuropathy.  
3. The two groups were matched for age and sex. 
4. The mean duration of treatment for diabetes mellitus in group 2 patients is 8.38 years 
which is statistically significant.  
5. The mean fasting blood sugar value in group 2 patients is 164.34mgs/dl which is 
statistically significant.  
6. The mean HbA1c value in group 2 patients is 9.07% which is statistically significant. 
7. The mean Total cholesterol value in group 2patients is 205.9mgs/dl whereas the mean 
value in group 1 patients is 202.08mgs/dl.  
8. The mean value of triglycerides in group 2 patients is 187.5mgs/dl which is statistically 
significant. 
9. The mean values of HDL, LDL, and VLDL were 56.78mgs/dl,111.62mgs/dl and 
36.88mgs/dl respectively in group 2 patients. In group 1 patients the mean HDL, LDL and 
VLDL were  55.549 mgs/dl, 111.34mgs/dl, 35.18mgs/dl respectively.   
10.  54% of patients in group 2 had systemic hypertension whereas in group 1 it was 28%. 
This difference is statistically significant. 
11.  The mean systolic blood pressure in group 1 patients is 138 mm of hg whereas in group 2 
patients it is 144 mm of hg. 
12.  The mean diastolic blood pressure in group 1 patients is 86 mm of hg whereas in group 2 
patients it is 90 mm of hg. 
13.  30% of patients in group 2 had macroalbuminuria which is statistically significant. 
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14.  The mean microalbuminuria level in group 2 patients is 66.60mgs/dl which is 
statistically significant. 
15.  The mean BMI in group 2 patients is 25.28. It is statistically significant. 
16.  In group 1patients, the mean height is 1.5788m. In group 2 patients, the mean height is 
1.585m. 
17.  28% of patients in group 2 had history of CAHD and this is statistically significant. 
18.  32% of patients in group 2 were smokers. This is statistically significant. 
19. 12% of patients in group 1 had postural hypotension whereas in group 2 28% of the 
patients were having postural hypotension. 
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CONCLUSION: 
 
Among the risk factors hyperglycemia is the modifiable risk factor for diabetic neuropathy, 
intensive glycemic control is the established therapy for reducing the incidence or slowing 
the progression of neuropathy. Other contributory factors include duration of diabetes, fasting 
blood sugar, HbA1c, serum Triglycerides, macroalbuminuria, microalbuminuria, Systemic 
hypertension, history of smoking, coronary artery heart disease, BMI.  Improved preventive 
care and earlier intervention may improve the disease outcome, prevent or delay the onset of 
neuropathy and consequently have a positive impact on patients quality of life and reduce the 
economic burden of diabetes and its complications. 
    
 
 
 
 
 
 
73 
 
BIBLIOGRAPHY 
1. Vinik AI, Park TS, Stansberry KB et al. Diabetic neuropathies. Diabetologia. 2000; 
43:957-73. 
2. FamuyiwaO.O,Sulimani R.A,LaajamM.A et al.Diabetes Mellitus in Saudi Arabia: the 
clinical pattern and complications in 1000 patients.Ann SaudiMed,1992,12:140-51.. 
3. Lehtinen JM, Uusitupa M, Siitonen O, Pyorala K. Prevalence of neuropathy in newly 
diagnosed NIDDM and non-diabetic control subjects. Diabetes 1989; 38:1307-1313. 
4. Harris MI, Eastman R, Cowie C. Symptoms of sensory neuropathy in adults with 
NIDDM in the U.S.  population. Diabetes Care 1993; 16:1446-1452. 
5. Dyck PJ, Kratz KM, Kames JL, et al. The prevalence by staged severity of various 
types of diabetic neuropathy, retinopathy, and  nephropathy in a population-based 
cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43:817-824. 
6. Melton LJ III, Dyck PJ. Epidemiology In: Dyck PJ, Thomas PK, Asbury AK, 
Winegrad Al, Porte D Jr., (eds.): Diabetic Neuropathy. Philadelphia, Saunders: 27-35 
15; 1987. 
7. Palumbo PJ, Elveback LR, W hisnant JP. Neurologic complications of diabetes 
mellitus: transient ischemic attack, stroke, and peripheral neuropathy. Adv Neurol 
1978; 19:593601. 
8. Pirart J. Diabetes and its degenerative complications: a prospective study of 4,400 
patients observed between 1947 and 1973. Diabetes Care 1978; 1:168-188. 
 
9. Ayad H.Diabetic neuropathy.Classification,clinical manifestations,diagnosis and 
management.Excerpta Medica,1977,1:222-4 
74 
 
10. DCCT Research Group.Factors in development of diabetic neuropathy. Baseline analysis 
of neuropathy in feasibility phase of diabetes control and complications trial. (DCCT). 
Diabetolgia,1988,37:476-89. 
11. Powers AC. Diabetes Mellitus. Harrisons Principles of Internal Medicine 17th Edition. Mc 
Graw Hill. 2275 – 2304. 
12.Vinik AI, Mitchell BD, Leichter SB, et al: Epidemiology of the complications of 
diabetes.   In: Leslie RDG, Robbins DC, ed. Diabetes: Clinical Science in 
Practice,  Cambridge, UK: Cambridge University Press; 1995:221-287.  
13. Vinik A, Mehrabyan A: Diabetic neuropathies.  Med Clin North Am  2004; 88(4):947- 
999. 
14. Young MJ, Boulton AJM, MacLeod AF, et al: A multicentre study of the prevalence of 
diabetic peripheral neuropathy in the United Kingdom hospital clinic 
population.  Diabetologia  1993; 36:1-5.  
15. Dyck PJ, Kratz KM, Karnes JL, et al: The prevalence by staged severity of various types 
of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The 
Rochester Diabetic Neuropathy Study.  Neurology  1993; 43:817-824.  
16. Holzer SE, Camerota A, Martens L, et al: Costs and duration of care for lower extremity 
ulcers in patients with diabetes.  Clin Ther  1998; 20:169-181.  
17. Caputo GM, Cavanagh PR, Ulbrecht JS, et al: Assessment and management of foot 
disease in patients with diabetes.  N Engl J Med  1994; 331:854-860.  
18. Pirart J: [Diabetes mellitus and its degenerative complications: a prospective study of 
4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)].  Diabete 
Metab  1977; 3:245-256.  
19. Smith A, Ramachandran P, Tripp S, Singleton J: Epidermal nerve innervation in impaired 
glucose tolderance and diabetes-associated neuropathy.  Neurology  2001; 57:1701-1704.  
75 
 
20. Pittenger GL, Ray M, Burcus NI, et al: Intraepidermal nerve fibers are indicators of 
small-fiber neuropathy in both diabetic and nondiabetic patients.  Diabetes 
Care  2004; 27:1974-1979.  
21. Vinik AI: Diabetic neuropathy, mobility and balance.  Geriatric Times  2003; 4(1):13-15.  
22. Resnick HE, Stansberry KB, Harris TB, et al: Diabetes, peripheral neuropathy, and old 
age disability.  Muscle Nerve  2002; 25:43-50.  
23. Vinik A: Diabetic neuropathy: pathogenesis and therapy.  Am J Med  1999; 107:17S-26S.  
24. Armstrong DG, Lavery LA, Harkless LB: Validation of a diabetic wound classification 
system. The contribution of depth, infection, and ischemia to risk of amputation.  Diabetes 
Care  1998; 21:855-859.  
25. Levitt NS, Stansberry KB, Wychanck S, Vinik AI: Natural progression of autonomic 
neuropathy and autonomic function tests in a cohort of IDDM.  Diabetes Care  1996; 19:751-
754.  
26. Rathmann W, Ziegler D, Jahnke M, et al: Mortality in diabetic patients with 
cardiovascular autonomic neuropathy.  Diabet Med  1993; 10:820-824.  
27. Maser RE, Mitchell BD, Vinik AI, Freeman R: The association between cardiovascular 
autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis.  Diabetes 
Care  2003; 26(6):1895-1901.  
28. Vinik AI, Maser RE, Mitchell BD, Freeman R: Diabetic autonomic neuropathy.  Diabetes 
Care  2003; 26(5):1553-1579.  
29. American Diabetes Association and American Academy of Neurology : Consensus 
statement: report and recommendations of the San Antonio conference on diabetic 
neuropathy.  Diabetes Care  1988; 11:592-597.  
30. Watkins PJ: Progression of diabetic autonomic neuropathy.  Diabet Med  1993; 10(Suppl 
2):77S-78S.  
76 
 
31. DCCT Research Group: The effect of intensive treatment of diabetes on the development 
and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J 
Med  1993; 329:977-986.  
32. DCCT Research Group: The effect of intensive diabetes therapy on the development and 
progression of neuropathy.  Ann Intern Med  1995; 122:561-568.  
33. Ziegler D, Cicmir I, Mayer P, Wiefels K, and Gries FA: Somatic and autonomic nerve 
function during the first year after diagnosis of type 1 (insulin-dependent) diabetes.  Diabetes 
Res  1988; 7:123-127.  
34. Partanen J, Niskanen L, Lehtinen J, et al: Natural history of peripheral neuropathy in 
patients with non–insulin-dependent diabetes mellitus.  N Engl J Med  1995; 333:89-94.  
35. Oh SJ: Clinical electromyelography: nerve conduction studies.   In: Oh SJ, ed. Nerve 
Conduction in Polyneuropathies,  2nd ed.. Baltimore: Williams & Wilkins; 1993:579-591.  
36. Kennedy WR, Wendelschafer-Crabb G, Johnson T: Quantitation of epidermal nerves in 
diabetic neuropathy.  Neurology  1996; 47:1042-1048.  
37. Herrmann DN, Griffin JW, Hauer P, et al: Epidermal nerve fiber density and sural nerve 
morphometry in peripheral neuropathies.  Neurology  1999; 53:1634-1640.  
38. Vinik A, Erbas T, Park T, et al: Dermal neurovascular dysfunction in type 2 
diabetes.  Diabetes Care  2001; 24:1468-1475.  
39. Smith AG, Russell J, Feldman EL, et al: Lifestyle intervention for pre-diabetic 
neuropathy.  Diabetes Care  2006; 29:1294-1299.  
40. Karamitsos DT, Didangelos TP, Athyros VG, Kontopoulos AG: The natural history of 
recently diagnosed autonomic neuropathy over a period of 2 years.  Diabetes Res Clin 
Pract  1998; 42:55-63.  
41. Ziegler D: Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and 
treatment.  Diabetes Metab Rev  1994; 10:339-383. 
77 
 
42. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve 
conduction and morphometry in diabetic neuropathy. Zenarestat Study 
Group. Neurology. Aug 11 1999;53(3):580-91. 
43. Ryle C, Donaghy M. Non-enzymatic glycation of peripheral nerve proteins in human 
diabetics. J Neurol Sci. Mar 1995;129(1):62-8. 
44.Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA. Oral treatment with alpha-lipoic acid 
improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes 
Care. Nov 2006;29(11):2365-70.  
45. Herman WH, Kennedy L: Underdiagnosis of peripheral neuropathy in type 2 
diabetes.  Diabetes Care  2005; 28:1480-1481.  
46. Vinik AI, Suwanwalaikorn S: Autonomic neuropathy.   In: DeFronzo RA, ed. Current 
Therapy of Diabetes Mellitus,  St. Louis: Mosby; 1997:165-176.  
47. Karpitskaya Y, Novak CB, Mackinnon SE: Prevalence of smoking, obesity, diabetes 
mellitus and thyroid disease in patients with carpal tunnel syndrome.  Am Plast 
Surg  2002; 48:269-273.  
48. Perkins B, Olaleye D, Bril V: Carpal tunnel syndrome in patients with diabetic 
polyneuropathy.  Diabetes Care  2002; 25:565-569.  
49. Chaudhuri KR, Davidson AR, Morris IM: Limited joint mobility and carpal tunnel 
syndrome in insulin dependent diabetes.  Br J Rheumatol  1989; 28:191-194.  
50. Vinik AI, Holland MT, LeBeau JM, et al: Diabetic neuropathies.  Diabetes 
Care 1992; 15:1926-1975.  
51. Vinik AI, Pittenger GL, Milicevic Z, Knezevic-Cuca J: Autoimmune mechanisms in the 
pathogenesis of diabetic neuropathy.   In: Eisenbarth RG, ed. Molecular Mechanisms of 
Endocrine and Organ Specific Autoimmunity,  Georgetown: Landes; 1998:217-251.  
78 
 
52. Steck AJ, Kappos L: Gangliosides and autoimmune neuropathies: classification and 
clinical aspects of autoimmune neuropathies.  J Neurol Neurosurg 
Psychiatry  1994; 57(suppl):26-28. 
53. Said G, Goulon-Goreau C, Lacroix C, Moulonguet A: Nerve biopsy findings in different 
patterns of proximal diabetic neuropathy.  Ann Neurol  1994; 35:559-569.  
54. Sander HW, Chokroverty S: Diabetic amyotrophy: current concepts.  Semin 
Neurol  1996; 16:173-178.  
55. Krendel DA, Costigan DA, Hopkins LC: Successful treatment of neuropathies in patients 
with diabetes mellitus.  Arch Neurol  1995; 52:1053-1061.  
56. Britland ST, Young RJ, Sharma AK, Clarke BF: Acute and remitting painful diabetic 
polyneuropathy: a comparison of peripheral nerve fibre pathology.  Pain  1992; 48:361-370.  
57. Stewart JD, McKelvey R, Durcan L, et al: Chronic inflammatory demyelinating 
polyneuropathy (CIDP).  J Neurol Sci  1996; 142:59-64.  
58. Sharma K, Cross J, Ayyar D, et al: Diabetic demyelinating polyneuropathy responsive to 
intravenous immunoglobulin therapy.  Arch Neurol  2002; 59:751-757.  
59. Bird SJ, Brown MJ: The clinical spectrum of diabetic neuropathy.  Semin 
Neurol  1996; 16:115-122.  
60. Hanson PH, Schumaker P, Debugne TH, Clerin M: Evaluation of somatic and autonomic 
small fibers neuropathy in diabetes.  Am J Phys Med Rehabil  1992; 71:44-47.  
61. McArthur JC, Stocks EA, Hauer P, et al: Epidermal nerve fiber density: normative 
reference range and diagnostic efficiency.  Arch Neurol  1998; 55:1513-1520.  
62. Stansberry KB, Hill MA, Shapiro SA, et al: Impairment of peripheral blood flow 
responses in diabetes resembles an enhanced aging effect.  Diabetes Care  1997; 20:1711-
1716.  
79 
 
63. Hirai A, Yasuda H, Joko M, et al: Evaluation of diabetic neuropathy through the 
quantitation of cutaneous nerves.  J Neurol Sci  2000; 172:55-62.  
64. Polydefkis M, Hauer P, Griffin JW, McArthur JC: Skin biopsy as a tool to assess distal 
small fiber innervation in diabetic neuropathy.  Diabetes Technol Ther  2001; 3:23-28. 
65. Griffin JW, McArthur JC, Polydefkis M: Assessment of cutaneous innervation by skin 
biopsies.  Curr Opin Neurol  2001; 14:655-659.  
66. Dalsgaard CJ, Rydh M, Haegerstrand A: Cutaneous innervation in man visualized with 
protein gene product 9.5 (PGP 9.5) antibodies.  Histochemistry  1989; 92:385-390.  
67. McCarthy BG, Hsieh ST, Stocks A, et al: Cutaneous innervation in sensory neuropathies: 
evaluation by skin biopsy.  Neurology  1995; 45:1848-1855.  
68. Dyck PJ: Detection, characterization and staging of polyneuropathy: assessed in 
diabetes.  Muscle Nerve  1988; 11:21-32.  
69. Vinik AI, Mitchell B: Clinical aspects of diabetic neuropathies.  Diabetes Metab 
Rev  1988; 4:223-253.  
70. Ziegler D, Hanefeld M, Ruhnau KJ, et al: Treatment of symptomatic diabetic peripheral 
neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized 
controlled trial (ALADIN Study).  Diabetologia  1995; 38:1425-1433.  
71. Feldman EL, Stevens MJ, Thomas PK, et al: A practical two-step quantitative clinical and 
electrophysiological assessment for the diagnosis and staging of diabetic 
neuropathy.  Diabetes Care  1994; 17:1281-1289.  
72. Cabezas-Cerrato J: The prevalence of diabetic neuropathy in Spain: a study in primary 
care and hospital clinic groups.  Diabeteologia  1998; 41:1263-1269.  
73. Bril V: NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic 
peripheral neuropathy.  Eur Neurol  1999; 41(suppl 1):8-13:8-13.  
80 
 
74. Hermenegildo C, Felipo V, Minana MD, et al: Sustained recovery of Na+-K+-ATPase 
activity in sciatic nerve of diabetic mice by administration of H7 or calphostin C, inhibitors of 
PKC.  Diabetes  1993; 42:257-262.  
75. Cameron NE, Cotter MA, Basso M, Hohman TC: Comparison of the effects of inhibitors 
of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction 
and tissue polyol pathway metabolites in streptozotocin-diabetic 
rats.  Diabetologia  1997; 40(3):271-281.  
76. Dyck PJ: Severity and staging of diabetic 
polyneuropathy.   In: Gries FA, Cameron NE, Low PA, Ziegler D, ed. Textbook of Diabetic 
Neuropathy,  Stuttgart: Thieme; 2003:170-175.  
77. Valk GD, de Sonnaville JJ, van Houtum WH, et al: The assessment of diabetic 
polyneuropathy in daily clinical practice: reproducibility and validity of Semmes Weinstein 
monofilaments examination and clinical neurological examination.  Muscle 
Nerve  1997; 20:116-118.  
78. Mayfield JA, Sugarman JR: The use of Semmes-Weinstein monofilament and other 
threshold tests for preventing foot ulceration and amputation in people with diabetes.  J Fam 
Pract  2000; 49(suppl):517-529.  
79. Bourcier ME, Ullal J, Parson HK, et al: Diabetic peripheral neuropathy: how reliable is a 
homemade 1-g monofilament for screening.  J Fam Pract  2006; 55:505-508.  
80. Kumar S, Fernando DJ, Veves A, et al: Semmes-Weinstein monofilaments: a simple, 
effective and inexpensive screening device for identifying diabetic patients at risk of foot 
ulceration.  Diabetes Res Clin Pract  1991; 13:63-67.  
81. Armstrong D, Lavery L, Vela S, et al: Choosing a practical screening instrument to 
identify patients at risk for diabetic foot ulceration.  Arch Intern Med  1998; 158:289-292. 
81 
 
82. Vinik AI, Suwanwalaikorn S, Stansberry KB, et al: Quantitative measurement of 
cutaneous perception in diabetic neuropathy.  Muscle Nerve  1995; 18:574-584.  
83. Liniger C, Albeanu A, Bloise D, Assal JP: The tuning fork revisited.  Diabetic 
Med  1990; 7:859-864.  
84. Shin JB, Seong YJ, Lee HJ, et al: Foot screening technique in diabetic populations.  J 
Korean Med Sci  2000; 15:78-82.  
85. Katoulis EC, Ebdon-Parry M, Lanshammar H, et al: Gait abnormalities in diabetic 
neuropathy.  Diabetes Care  1997; 20:1904-1907.  
86. Vileikyte L, Hutchings G, Hollis S, Boulton AJM: The tactile circuimferential 
discriminator: a new simple screening device to identify diabetic patients at risk of foot 
ulceration.  Diabetes Care  1997; 20:623-626.  
87. Jaradeh SS, Prieto TE, Lobeck LJ: Progressive polyradiculoneuropathy in diabetes: 
correlation of variables and clinical outcome after immunotherapy.  J Neurol Neurosurg 
Psychiatry  1999; 67:607-612.  
88. Periquet MI, Novak V, Collins MP, et al: Painful sensory neuropathy: prospective 
evaluation using skin biopsy.  Neurology  1999; 53:1641-1647.  
89. Arezzo JC: The use of electrophysiology for the assessment of diabetic 
neuropathy.  Neurosci Res Comm  1997; 21:13-22.  
90. Amthor KF, Dahl-Jorgensen K, Berg TJ, et al: The effect of 8 years of strict glycaemic 
control on peripheral nerve function in IDDM patients: the Oslo 
Study.  Diabetologia  1994; 37:579-584.  
91. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose 
control with metformin on complications in overweight patients with type 2 diabetes 
(UKPDS 34).  Lancet  1998; 352:854-865.  
82 
 
92. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in 
patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised 
study.  Lancet  1999; 353:617-622.  
93. Didangelos TP, Karamitsos DT, Athyros VG, Kourtoglou GI: Effect of aldose reductase 
inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic 
neuropathy.  J Diabetes Complications  1998; 12:201-207.  
94. Greene DA, Arezzo JC, Brown MB: Effect of aldose reductase inhibition on nerve 
conduction and morphometry in diabetic neuropathy. Zenarestat Study 
Group.  Neurology  1999; 53:580-591. 
95. Johnson BF, Law G, Nesto R, et al: Aldose reductase inhibitor zopolrestat improves 
systolic function in diabetics (abstract).  Diabetes  1999; 48(suppl 1):A133.  
96. Hotta N, Toyota T, Matsuoka K, the SNK-860 Diabetic Neuropathy Study Group , et 
al: Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral 
neuropathy.  Diabetes Care  2001; 24:1776-1782.  
97. Hotta N, Akanuma Y, Kawamori R, et al: Long-term clinical effects of epalrestat, an 
aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, 
comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.  Diabetes 
Care  2006; 29:1538-1544.  
98. Ziegler D, Schatz H, Conrad F, et al: Effects of treatment with the antioxidant alpha-
lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized 
controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome 
Neuropathie.  Diabetes Care  1997; 20:369-373.  
99. Ziegler D, Gries FA: Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac 
autonomic neuropathy.  Diabetes  1997; 46(suppl 2):S62-S66.  
83 
 
100. Ziegler D, Hanefeld M, Ruhnau KJ, et al: Treatment of symptomatic diabetic 
polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized 
controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in 
Diabetic Neuropathy.  Diabetes Care  1999; 22:1296-1301.  
101. Jamal GA: The use of gamma linolenic acid in the prevention and treatment of diabetic 
neuropathy.  Diabet Med  1994; 11:145-149.  
102. Dyck PJ: Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy? The 
1988 Robert Wartenberg lecture.  Neurology  1989; 39:111-118.  
103. Kles KA, Vinik AI: Pathophysiology and treatment of diabetic peripheral neuropathy: 
the case for diabetic neurovascular functions as an essential component.  Curr Diabetes 
Rev  2006; 2:131-145.  
104. Vinik A, Bril V, Kempler P, for the MBBQ Study , et al: Treatment of symptomatic 
diabetic peripheral neuropathy with protein kinase Cb inhibitor ruboxistaurin mesylate during 
a 1-year randomized, placebo-controlled, double-blind clinical trial.  Clin 
Ther  2005; 27:1164s-1180s.  
105. Miyauchi Y, Shikama H, Takasu T, et al: Slowing of peripheral motor nerve conduction 
was ameliorated by aminoguanidine in streptozocin-induced diabetic rats.  Eur J 
Endocrinol  1996; 134:467-473.  
106. Schmidt RE, Dorsey DA, Beaudet LN, et al: Effect of aminoguanidine on the frequency 
of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats 
with streptozotocin-induced diabetes.  Diabetes  1996; 45:284-290.  
107. Nargi SE, Colen LB, Liuzzi F, et al: PTB Treatment restores joint mobility in a new 
model of diabetic cheirothropathy (abstract).  Diabetes  1999; 48(suppl 1):A17.  
84 
 
108. Apfel SC, Kessler JA, Adornato BT, NGF Study Group, et al: Recombinant human 
nerve growth factor in the treatment of diabetic polyneuropathy.  Neurology  1998; 51:695-
702.  
109. Vinik AI: Treatment of diabetic polyneuropathy (DPN) with recombinant human nerve 
growth factor (rhNGF). (Abstract).  Diabetes  1999; 48(Suppl 1):A54-A55.  
110. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic pain: an 
update and effect related to mechanism of drug action.  Pain  1999; 83:389-400.  
111. Said G, Bigo A, Ameri A, et al: Uncommon early-onset neuropathy in diabetic 
patients.  J Neurol  1998; 245:61-68.  
112. Jarvis B, Coukell AJ: Mexiletine. A review of its therapeutic use in painful diabetic 
neuropathy.  Drugs  1998; 56:691-707.  
113. Harati Y, Gooch C, Swenson M, et al: Double-blind randomized trial of tramadol for the 
treatment of the pain of diabetic neuropathy.  Neurology  1998; 50:1842-1846.  
114. Harati Y, Gooch C, Swenson M, et al: Maintenance of the long-term effectiveness of 
tramadol in treatment of the pain of diabetic neuropathy.  J Diabetes 
Complications  2000; 14:65-70.  
115. Nelson KA, Park KM, Robinovitz E, et al: High-dose oral dextromethorphan versus 
placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology  1997; 48:1212-
1218.  
116. McQuay H, Tramer M, Nye B, et al: A systematic review of antidepressants in 
neuropathic pain.  Pain  1996; 68:217-227.  
117. Joss JD: Tricyclic antidepressant use in diabetic neuropathy. Ann 
Pharmacother 1999; 33:996-1000.  
118. McQuay H, Carroll D, Jadad AR, et al: Anticonvulsant drugs for management of pain: a 
systematic review.  BMJ  1995; 311:1047-1052.  
85 
 
119. Vinik AI: Advances in diabetes for the millennium: new treatments for diabetic 
neuropathies.  MedGenMed  2004; 6(3 suppl):13.  
120. LaRoche SM, Helmers SL: The new antiepileptic drugs: scientific 
review.  JAMA  2004; 291:605-614.  
121. Nelson ME, Fiatarone MA, Morganti CM, et al: Effects of high-intensit strength training 
on multiple risk factors for osteoporotic fractures. A randomized controlled 
trial.  JAMA  1994; 272:1909-1914.  
122. Liu-Ambrose T, Khan KM, Eng JJ, et al: Resistance and agility training reduce fall risk 
in women aged 75 to 85 with low bone mass: a 6-month randomized, controlled trial.  J Am 
Geriatr Soc  2004; 52:657-665.  
123. Somers DL, Somers MF: Treatment of neuropathic pain in a patient with diabetic 
neuropathy using transcutaneous electrical nerve stimulation applied to the skin of the lumbar 
region.  Phys Ther  1999; 79:767-775.  
124. Laederach-Hofmann K, Weidmann P, Ferrari P: Hypovolemia contributes to the 
pathogenesis of orthostatic hypotension in patients with diabetes mellitus.  Am J 
Med  1999; 106:50-58. 
125. Ashok S, Ramu M, Deepa R, Mohan V. Prevalence of neuropathy in type 2 diabetic 
patients attending a diabetes centre in South India. JAPI 2002; 50: 546-50. 
126.Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral 
neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB 
IDDM Complications Study. Diabetologia 1996;39: 1377-84. 
127.J.E. Shaw, A.M. Hodge, M. de Courten, G.K. Dowse, Gareeboo, J. Tuomilehto, et al., 
Diabetic neuropathy in Mauritius: prevalence and risk factors, Diabetes Res. Clin. Pract. 
1998; 42: 131–39. 
86 
 
128.Booya F, Bandarian F, Larijani B et al .Potential risk factors for diabetic neuropathy: a 
case control study.BMC Neurol. 2005; 5: 24.  
129. Barbosa A P, Medina J L, Ramos E P et al. Prevalence and risk factors of clinical 
diabetic neuropathy in a Portuguese primary health care population. Diabetes & Metabolism 
2001; 27: 496. 
130.Ugoya S O, Ugoya T A, Puepet F H, Agaba E I, Ogunniyi A O. Risk determinants of 
diabetic peripheral neuropathy in Jos, North-Central Nigeria. Journal of Chinese Clinical 
Medicine,2008; 3(5):285-291.    
131. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto 
Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care, 2000; 23(2): 
B21-9. 
132. Stratton IM, Adler AI, Neil HAW et al. Association of glycaemia with macrovascular 
and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational 
study. BMJ 2000; 321:405–12. 
133.Albers JW, Herman WH, Pop-Busui R et al. Effect of prior intensive insulin treatment 
during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in 
type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications 
(EDIC) Study. Diabetes Care. 2010 May;33(5):1090-6. 
134. Lu B, Yang Z, wang M et al. High prevalence of diabetic neuropathy in population 
based patients diagnosed with type 2 diabetes in Shanghai downtown. Diabetes Research And 
Clinical Practice. 2010; 88: 289-294. 
135. Diabetes Control and Complications Research Group. The effect of intensive treatment 
of diabetes on the development and progression of long-term complications of diabetes 
mellitus. New Eng J Med 1993; 329: 977–986. 
87 
 
 136. Tesfaye S, Chaturvedi N, Eaton S E M et al. Vascular Risk Factors and Diabetic 
Neuropathy.N Engl J Med 2005; 352:341-350. 
 137. Janghorbani M, Rezvanian H, Kachooei A et al. Peripheral neuropathy in type 2 
diabetes mellitus in Isfahan, Iran: Prevalence and risk factors. Int j Diabetes & Metabolism. 
2006; 14 : 126 – 133. 
 138. Wiggin T D, Sullivan K A, Pop-Busui R et al. Elevated Triglycerides Correlate with 
Progression of Diabetic Neuropathy. Diabetes 2009; 58(7) :1634 – 40. 
139. Tomlin AM, Dovey SM, Tilyard MW. Risk factors for hospitalization due to diabetes 
complications. Diabetes Res Clin Pract 2008;80:244–252. 
140.Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, Kohner EM. 
Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 
diabetes. Diabetes Care 2001;24: 284–289. 
141.Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in 
insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes 
Complications 2001;15:113–119. 
142. Davis TME, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral 
sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 
2008;51:562–566. 
143. Maser R E, Steenkiste A R, Dorman J S et al. Epidemiological correlates of diabetic 
neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. 
Diabetes 1989; 38: 1456 – 61. 
144. Elliott J, Tesfaye S, Chaturvedi N et al. Large – Fiber Dysfunction in Diabetic 
Peripheral Neuropathy Is Predicted by Cardiovascular Risk Factors. Diabetes Care 2009; 32 
(10) : 1896 – 1900.  
88 
 
145. Davis T M E, Yeap B B, Davis W A et al. Lipid – lowering therapy and peripheral 
sensory neuropathy in type 2 diabetes: The Fremantle Diabetes study. Diabetologia 2008; 51 : 
562 – 66. 
146. Turner R, Holman R, Stratton I et al. Tight blood pressure control and risk of 
macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 
317: 703 – 13 . 
147. Harris M, Eastman R, Cowie C et al. Symptoms of sensory neuropathy in adults with 
NIDDM in the U.S. population. Diabetes Care.1993 Nov;16(11):1446-52. 
148.Cohen J A, Jeffers B W, Faldut D et al.Risks For Sensorimotor Peripheral Neuropathy 
And Autonomic Neuropathy In Non-Insulin-Dependent Diabetes Mellitus (NIDDM). Muscle 
Nerve 1998; 21: 72–80. 
149. Schrier R W, Estacio R O, Jeffers B et al .Appropriate Blood Pressure Control in 
NIDDM (ABCD) Trial. Diabetologia 1996; 39: 1646–54. 
150.  Lluch I, Hernandez H, Real J T et al. Cardiovascular autonomic neuropathy in Type 1 
diabetic patients with and without peripheral neuropathy. Diabetes Research and Clinical 
Practice 1998; 42: 35 – 40. 
151. Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor 
of diabetic retinopathy,  neuropathy, and cardiovascular disease in NIDDM. Diabetes Care. 
1996 Nov;19(11):1243-8. 
152. Coppini D V, Spruce M C, Thomas P et al. Established diabetic neuropathy seems 
irreversible despite improvements in metabolic and vascular risk markers – a retrospective 
case – control study in a hospital patient cohort. Diabet.Med. 2006; 23 : 1016 – 20. 
153. Mitchell BD, Hawthorne VM, Vinik AI et al. Cigarette smoking and neuropathy in 
diabetic patients. Diabetes Care 1990; 13:434-437. 
89 
 
154. Christen WG, Manson JE, Bubes V, et al: Risk factors for progression of distal 
symmetric polyneuropathy in type 1 diabetes mellitus. Sorbinil Retinopathy Trial Research 
Group. Am J Epidemiol 1999;150:1142 – 51. 
155.  Reichard P: Risk factors for progression of microvascular complications in the 
Stockholm . Diabetes Intervention Study (SDIS). Diabetes Res Clin Pract 1992; 16:151-156. 
156.Adler AI, Boyko EJ, Ahroni JH et al. Risk factors for diabetic peripheral sensory  
neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care. 1997 
Jul;20 (7):1162-7. 
157. Kasim K, Amar M, Sadek AAE et al. Peripheral neuropathy in type 2 diabetic patients 
attending diabetic clinics in Al- Azhar University Hospitals, Egypt. International Journal of 
Diabetes Melitus 2010; 2 : 20 – 23. 
158. Owlabi MO. Aggregate cardiovascular risk is a stronger statistical correlate of clinically 
evident diabetic peripheral neuropathy than HbA1c alone. J Natl Med Assoc 2010; 102(8): 
707 – 12. 
159. Bruce S G, Young K et al. Prevalence and Risk factors for Neuropathy in a Canadian 
First Nation Community. Diabetes Care 2008; 31 : 1837 – 41. 
160. Gadia MT, Natori N, Ramos LB et al. Influence of height on quantitative sensory, 
nerve-conduction, and clinical indices of diabetic peripheral neuropathy. Diabetes Care 1987; 
10(5):613-6. 
161. Sosenko JM, Gadia MT, Fournier AM et al. Body stature as a risk factor for diabetic 
sensory neuropathy. Am J Med 1986; 80:1031-34. 
162. Robinson LR, Stolow WC, Rubner DE et al. Height is an independent riskfactor for 
neuropathy in diabetic men. Diabetes Res Clin Pract 1992;16:97-102. 
 
 
90 
 
                                  PROFORMA 
Name:                                 Age:                            Sex: 
Occupation:                      Address:                   OP/IP NO: 
History: 
1. Age at the diagnosis of diabetes 
2. Duration of treatment for diabetes 
3. H/O Smoking 
4. H/O Hypertension; CAHD ; Stroke 
Neuropathic symptoms: 
H/o numbness or coldness of feet 
H/o pricking sensation in feet 
H/o deep or burning sensation in feet 
H/o unusual difficulty in climbing stairs 
H/o dizziness on standing 
H/o chronic diarroea ( at night ) 
H/o Gustatory sweating 
H/o Erectile dysfunction 
TREATMENT HISTORY: 
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ANHROPOMETRY: 
Height:                         Weight:                       BMI: 
Waist Circumference:                        Hip circumference: 
Waist/ Hip ratio : 
Blood pressure: Supine:                          Standing: 
 
INVESTIGATIONS: 
 
HbA1c: 
Fasting Blood sugar: 
Post prandial Blood Sugar: 
Urea: 
Creatinine: 
HB%: 
Lipid profile: 
HDL                       TGL                       LDL                                  VLDL 
Albuminuria: 
Microalbuminuria: 
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8 ramaiyan 70 M 7 9.5 188 286 188 167 53 102 33 nil 74 150 90 1.7 70 24 yes no no no 
29 2 33 
1219/
04 murugan 60 M 9 8.8 148 232 193 261 57 83 52 nil 68 138 74 1.64 57 21 no no no no 
30 2 34 
1315/
04 
idumbaiya
n 54 M 6 8.2 148 284 257 276 63 139 55 yes 
 
127 90 1.62 56 21 no no no yes 
31 2 35 
114/0
3 
duraimani
ckam 67 M 12 10.2 200 336 193 217 58 92 43 nil 71 135 92 1.66 57 20 no no no no 
32 2 36 
1412/
07 
balasubra
maniam 42 M 15 11.2 124 228 188 209 57 89 42 yes 
 
135 92 1.66 57 20 no no no no 
33 2 37 
411/0
4 veeraiyan 62 M 11 9.1 228 364 261 197 58 164 39 nil 18 131 89 1.56 62 25 no yes no no 
34 2 38 
1311/
05 
sadhasiva
m 70 M 5 8.6 256 416 219 168 55 130 34 nil 59 132 86 1.52 55 23 yes yes no no 
35 2 40 
1131/
08 manikaraj 70 M 7 6.1 100 178 187 179 56 95 36 nil 31 155 111 1.68 62 21 yes no no yes 
36 2 41 
239/0
5 sundaram 80 M 8 7.3 98 134 189 147 52 108 29 nil 16 133 74 1.61 54 20 no no no no 
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37 2 42 
1323/
06 
loganatha
n 56 M 5 6.2 134 228 178 161 53 93 29 nil 29 171 113 1.66 76 27 yes no yes no 
38 2 43 
233/0
2 
abdul 
hameed 54 M 6 5.3 112 132 184 179 56 92 36 nil 23 143 93 1.59 62 24 yes no no no 
39 2 51 
1411/
08 sethu 67 M 6 8.6 146 212 187 172 54 99 34 nil 66 122 76 1.62 70 26 no no no no 
40 2 52 
611/0
7 devdas 43 M 5 13.1 150 264 207 181 56 115 36 nil 97 127 79 1.49 80 36 yes no no no 
41 2 53 
2313/
08 
saarangap
pan 62 M 11 5.7 100 176 195 174 49 111 35 yes 
 
135 90 1.69 70 24 no no no no 
42 2 59 
3103/
06 
paneersel
vam 62 M 10 6.3 114 189 191 172 55 102 34 nil 27 150 100 1.5 60 26 yes no yes no 
43 2 60 
1848/
08 santhana 56 M 4 8.1 211 316 187 149 51 106 30 nil 39 130 80 1.6 62 24 no no no yes 
44 2 61 
411/0
5 sebastein 67 M 10 6.3 98 134 174 139 51 95 28 nil 25 122 76 1.62 67 25 no no no yes 
45 2 72 
1621/
10 arpudhan 60 M 8 6.4 112 168 207 184 59 111 37 yes 
 
150 100 1.54 64 26 yes no no yes 
46 2 73 
1313/
08 
veemaraja
n 73 M 4 6.6 114 145 208 211 62 104 42 nil 49 140 90 1.68 76 26 yes yes yes no 
47 2 75 
2083/
08 sayed 74 M 4 5.8 136 123 176 161 59 85 32 nil 22 170 102 1.6 77 30 yes no no no 
48 2 76 
958/0
7 
kaliyamoo
rthy 66 M 3 8.7 144 211 191 218 53 94 44 nil 47 120 80 1.65 78 28 yes yes yes yes 
49 2 81 
1679/
09 
mahendra
n 51 M 5 11.6 237 404 267 241 58 161 48 yes 
 
172 116 1.55 62 25 yes yes no no 
50 2 97 
732/0
2 moorthy 60 M 8 7.8 162 288 259 203 61 157 41 yes 
 
156 118 1.55 60 24 yes yes no no 
51 1 3 
1330/
02 ganesan 53 M 7 8.1 153 228 191 188 57 96 38 nil 85 128 85 1.6 52 20 no no no 
 
52 1 22 
311/0
7 
murugana
ndhan 43 M 6 8.3 212 289 192 163 51 108 33 yes 
 
142 81 1.61 70 27 no no no no 
53 1 23 
2131/
05 paulraj 60 M 4 8.1 72 116 201 183 56 108 37 nil 42 130 90 1.55 60 24 no no yes 
 
54 1 24 
10963
96 ganesan 73 M 18 5.9 308 304 197 173 58 102 34 nil 22 134 78 1.55 58 24 no no no no 
55 1 39 4151/ rajappa 46 M 5 5.6 285 286 262 173 55 172 35 nil 27 100 70 1.59 57 22 no no no no 
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08 
56 1 44 
175/1
0 
govindasa
my 73 M 2 6.7 121 213 228 179 55 137 36 nil 31 147 97 1.51 48 21 no no no yes 
57 1 45 
550/0
2 
rangaraja
n 64 M 10 10.8 114 189 187 162 54 101 32 nil 79 129 82 1.74 59 19 no no no no 
58 1 46 
1171/
08 
panjanath
an 60 M 5 6.1 122 206 193 171 56 103 34 nil 24 145 94 1.56 66 27 yes no no no 
59 1 47 
789/0
0 saroja 58 F 4 5.9 112 187 181 161 59 89 33 nil 19 135 72 1.45 56 26 yes yes no no 
60 1 48 
414/0
8 
rajalaksh
mi 52 F 6 12.7 118 126 189 157 48 110 31 nil 109 152 88 1.49 46 20 no no no no 
61 1 49 
1319/
09 mahadevi 49 F 5 6.7 168 304 178 149 56 92 30 nil 33 153 114 1.54 50 21 no no no no 
62 1 50 
615/0
7 
john 
britto 53 M 5 7.9 105 234 271 213 62 166 43 nil 47 155 110 1.59 64 25 no no no no 
63 1 54 
1172/
05 selvarani 61 F 7 5.5 132 188 204 181 56 112 36 nil 23 138 92 1.4 55 28 no no yes 
 
64 1 55 
516/0
1 ramarasu 58 M 4 6.1 108 168 202 166 54 115 33 nil 24 163 87 1.58 55 22 no no no no 
65 1 56 
220/0
9 rasammal 48 F 6 10.8 123 188 209 161 58 111 40 nil 67 159 91 1.54 84 35 no no no no 
66 1 57 
128/0
6 
ragina 
mary 61 F 4 11.6 180 224 211 189 62 111 38 nil 49 140 80 1.57 72 29 yes no no no 
67 1 58 
424/0
5 lalitha 57 F 17 6.7 223 304 183 162 54 97 32 yes 
 
180 94 1.5 54 24 yes yes no no 
68 1 62 
753/0
5 
varadaraja
n 51 M 5 9.2 94 150 212 196 57 116 39 nil 85 120 80 1.65 60 22 no no no no 
69 1 63 
9101/
03 
rangamm
al 60 F 7 6.1 240 256 192 173 56 101 35 nil 24 120 80 1.4 45 22 no no no no 
70 1 64 
2216/
09 rasu 50 M 5 5.7 130 240 196 167 49 114 33 nil 19 120 80 1.67 51 18 no no yes 
 
71 1 65 
2104/
07 john  40 M 3 5.9 123 268 207 183 56 114 37 nil 31 120 80 1.55 50 20 no no no no 
72 1 66 
754/1
0 rajendran 55 M 3 14.1 160 236 219 196 57 123 39 nil 39 130 80 1.62 64 24 no no no yes 
73 1 67 
3405/
05 amsavalli 67 F 4 5.9 168 213 231 186 55 139 37 nil 22 110 70 1.42 42 20 no no no no 
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74 1 68 
1856/
08 
vijayalaks
hmi 54 F 4 6.1 150 240 169 127 46 98 25 nil 24 120 80 1.43 45 22 no no no no 
75 1 69 
2334/
08 
ramalinga
m 42 M 3 5.7 119 254 197 181 56 105 36 nil 21 130 90 1.85 75 21 no no no no 
76 1 70 
3004/
02 lakshmi 70 F 15 6.1 142 264 187 149 55 102 30 nil 27 130 80 1.46 45 21 no no no no 
77 1 71 
1824/
06 
subbulaks
hmi 60 F 3 6.2 123 222 234 201 58 136 40 yes 
 
110 70 1.52 58 25 no no no no 
78 1 74 
1127/
09 appa rao 68 M 25 6.3 102 180 189 148 53 106 30 nil 29 170 90 1.66 61 22 yes no no no 
79 1 77 
10907
98 
vaithialing
am 60 M 3 7.9 112 256 173 182 61 76 36 nil 68 132 84 1.62 58 22 no no no no 
80 1 78 
644/1
0 mariyadas 45 M 3 5.6 162 314 198 167 59 106 33 nil 17 98 62 1.62 60 22 no no yes yes 
81 1 79 
227/0
3 amanullah 62 M 8 13.6 92 262 179 192 61 80 38 nil 88 178 88 1.58 50 20 yes no no no 
82 1 80 
115/0
9 sannasi 60 M 8 8.8 116 208 189 217 59 87 43 yes 
 
128 72 1.66 60 21 yes yes no no 
83 1 82 
571/0
7 sivakumar 55 M 3 6.5 122 173 169 178 55 78 36 yes 
 
182 114 1.65 57 20 no no no no 
84 1 83 
1897/
09 
swaminat
han 73 M 3 7.9 152 242 188 217 61 84 43 nil 52 160 108 1.61 60 23 yes no no no 
85 1 84 
2376/
08 
govidaraja
n 64 M 3 9.7 176 240 173 146 51 93 29 nil 67 140 70 1.64 65 24 no no no no 
86 1 85 
1705/
03 rajapillai 48 M 15 12.1 102 206 168 137 49 92 27 nil 46 170 100 1.73 68 22 yes no no yes 
87 1 86 
1228/
07 gopal 75 M 5 5.8 104 168 168 131 47 95 26 nil 24 130 90 1.48 45 20 no no no no 
88 1 87 
2230/
09 sundaraj 50 M 4 7.6 150 316 207 194 55 113 39 nil 39 162 106 1.58 54 21 yes yes no no 
89 1 88 
11013
72 selvi 57 F 10 10.7 132 268 171 203 56 74 41 nil 71 136 90 1.53 55 23 no no no no 
90 1 89 
11005
90 uma 48 F 15 8.6 140 277 207 186 55 115 37 nil 41 140 90 1.39 45 23 yes no yes no 
91 1 90 
1894/
09 ganesan 68 M 10 6.1 96 136 247 178 61 150 36 nil 22 156 100 1.62 65 24 yes no no no 
92 1 91 
1488/
06 ukham 54 M 4 7.6 124 254 216 162 54 130 32 nil 48 120 80 1.62 49 18 no no no no 
93 1 92 
1739/
04 dharmaraj 57 M 8 8.1 128 266 213 198 57 116 40 nil 41 124 76 1.75 62 20 no no no no 
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94 1 93 
648/0
3 
arumuga
m 55 M 4 5.9 133 297 187 162 54 101 32 nil 23 152 104 1.53 65 27 yes yes no yes 
95 1 94 
1049/
08 
palanisam
y 51 M 5 15.7 112 224 243 102 57 146 40 nil 62 148 96 1.61 52 20 yes no no no 
96 1 95 
1802/
10 kumar 41 M 3 6.1 102 210 181 157 49 101 31 nil 27 110 70 1.67 70 25 no no yes no 
97 1 96 
2511/
07 
govindaraj
u 60 M 4 6.1 177 326 247 169 53 161 33 nil 22 120 76 1.63 66 24 no no no no 
98 1 98 
1141/
10 kamaraj 45 M 4 8.2 167 314 237 196 58 140 39 nil 48 118 74 1.79 73 22 no no no no 
99 1 99 
1492/
10 thangaraj 60 M 3 6.1 237 326 187 163 54 101 32 nil 27 120 78 1.71 68 23 no no no no 
100 1 
10
0 
11039
89 
muthuku
maran 49 M 5 10.8 124 285 241 198 57 144 40 nil 46 130 80 1.65 55 20 no no no no 
